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ABSTRACT
The rise of “superbugs” – antibiotic resistant infection-causing bacteria

- poses a

catastrophic threat to public health, and prompts the investigation of new drug targets.
In this work, the inhibition of specific proteins in bacterial DNA replication machinery
– a rich source of new targets - was investigated.
The single stranded DNA-binding protein, SSB, is an interaction hub that engages in
vital interactions with several partner proteins through a flexible C-terminal peptide
motif (DDDIPF; SSB-Ct). Based on available crystal structures of SSB-Ct with partner
proteins, molecular dynamics simulations were used to identify mobile elements of
SSB-Ct and important interactions in SSB-Ct binding-pockets.
Fragment-based screening using various methods was undertaken, targeting the SSBbinding partner DnaG, the replicative primase from E. coli. Initially two fragment
libraries (by Zenobia Therapeutics and the Monash Institute of Pharmaceutical Science)
containing ~1600 fragments were screened against DnaG primase using SPR
competition and STD-NMR assays. The binding confirmation and binding site location
of identified fragments was confirmed by ligand- and protein-based NMR techniques.
Common features were identified in some fragment hits: carboxylic group containing
aromatic compounds.
In silico fragment-to-hit optimisation led to the identification of phenoxy-phenyl
tetrazoles; ZINC72447025 and CDS001350 with 1.3 mM and 1.2 mM binding
affinities. It was hypothesized that these compounds could inhibit other proteins that
bind to SSB-Ct. The tetrazole derivatives and other fragment hits were shown binding
to other SSB-Ct binding partners such as E. coli χ subunit of Pol III, PriA, RNAse HI
and A. baumannii χ.
This work demonstrates the potential for inhibitions SSB/binding partner interactions,
and the possibility of inhibiting multiple SSB-binding proteins with similar ligands.
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Chapter 1
General Introduction

Chapter 1: General Introduction

1.1 The Discovery of Antibiotics: an Overview
In everyday life, the human body interacts with an untold number of microorganisms.
While most are harmless, some are dangerous enough to be deadly. Many antibiotics
available today were originally extracted from natural products. After the discovery of
the first antibiotics in early 1930s, many more effective compounds have been
introduced into everyday clinical practice. Figure 1.1 provides a historical overview of
antibiotic discovery.

Figure 1.1. Timeline of discovery of antibiotics. Based on (Fischbach and Walsh, 2009).

In recent decades, only a few new groups of antibiotics have been identified; from 1960
till 2000 there was an “innovation gap” where no new classes of antibiotics were
introduced (J H Powers, 2004). In fact, only a handful of new classes of antibacterial
drugs have been approved by FDA since 2000: mutilins, lipopeptides, and
oxazolidones.
Pathogenic bacteria resistant to antibiotics have become a matter of grave concern.
Bacterial pathogens resistant to all clinically available antibiotics have been identified
(Heinemann et al., 2000; Longley and Johnston, 2005). Strains in question include
methicillin-resistant Staphylococcus aureus and various strains of Mycobacterium
tuberculosis, Acinetobacter baumannii and Pseudomonas aeruginosa (Figure 1.2).
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Figure 1.2. Micrographs of the resistant strains of S. aureus, M. tuberculosis, A. baumannii, P.
aeruginosa. Figure reproduced from (Fischbach and Walsh, 2009).

1.2 Steps Involved in the Discovery of New Drugs
The discovery of new drugs takes place in several steps and involves a range of
specialists from biologists to clinicians. Today, drug discovery tends to begin with the
identification of targets followed by screening of chemical libraries to identify
compounds inhibiting or activating the function of the target. The identified compounds
are optimised with respect to increasing the affinity and specificity to the target. The
optimised compound is then tested for ADME (absorption, distribution, metabolism and
elimination), followed by intensive preclinical and clinical trials, where the drug
candidate is tested on humans. If these are successful, the new drug is registered with
regulatory bodies (Figure 1.3). It is important to note that failure may be encountered at
any step.

3
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Target
discovery

Drug
Discovery

Safety &
Drug
Metabolism

Clinical
PhasesI-II

Clinical
Phase III

Registration

Figure 1.3. Steps involved in the drug discovery process starting from target identification to registration
of drug by a regulatory organization (in the US: the Food and Drug Administration).

1.3 Drug Targets
Target identification is one of the most important steps in drug discovery projects.
Identification of a suitable target increases the chance of success for further hit-to-lead
identification. A recent analysis of AstraZeneca’s research and development programs
has revealed that the failure of discovery projects is very often related to a lack of
information regarding the biology of a particular disease, which commonly is
attributable to a poorly chosen target (Cook et al., 2014). The importance of target
validation should therefore never be underestimated.
In recent years, an increasingly popular drug discovery strategy is “multi-target drug
discovery”. The identification of drugs affecting multiple targets increases the chances
of success, and overcomes the problem of resistance. Several agents like multikinase
and EGFR family inhibitors have been identified that modulate multiple targets
(Morphy, 2010).

1.3.1 Antibiotic Targets
Since 1930 a few groups of antibiotics have been identified targeting cell wall synthesis,
protein synthesis etc. All clinically used antibiotics and their targets are summarized in
Figure 1.4 (Lewis, 2013).
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Figure 1.4. A bacterial cell with all currently available processes targeted in antibiotic discovery. Figure
reproduced from (Lewis, 2013).

In order to overcome antibacterial resistance, there is a need to identify new drug
targets. Bacterial DNA replication, recombination and repair is an underexploited drug
target, involving many protein-protein and protein-DNA interactions (Schaeffer et al.,
2005; Robinson et al., 2012).

1.4.1 High-Throughput Screening Versus Fragment-Based Screening
Large pharmaceutical companies traditionally relied on high-throughput screening
(HTS) to identify hits. HTS involves the use of sizeable chemical libraries (103 to 107
compounds), comprised of chemically diverse, largely drug-like structures (Walters and
Namchuk, 2003; Macarron et al., 2011; Phillip Gribbon and Andreas, 2005). HTS has
been reliant on the use of automated enzymatic or cell-based assays for screening,
which are prone to false positive hits due to non-specific and off-target interactions
5
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(Philip Gribbon and Sewing, 2003). One relatively new but increasingly popular
approach in drug discovery is fragment-based screening (FBS), an alternative to HTS
with a broader choice of screening method (Rees et al., 2004). FBS starts from
relatively small building blocks known as fragments. The fragments are typically
chosen to satisfy the ‘Rule of Three’, introduced by Astex pharmaceuticals (Congreve et
al., 2003). The rule of three prescribes that fragments should have a molecular mass of
< 300 Da, up to three hydrogen bonds donors, up to three hydrogen bond acceptors,
number of rotatable bonds < 3 and calculated logP (clogP) of < 3. These rules help to
ensure that lead compounds with drug-like physicochemical properties are ultimately
produced. Fragments generally contain aromatic rings with chemically diverse
functional groups. During optimisation of a fragment hit, the MW is increased, along
with the potency of the compound. This stepwise engineering of a small molecule
minimizes unfavourable steric and electrostatic interactions in the targeted pocket
(Congreve et al., 2003). Additional rules have recently been proposed regarding the
various physicochemical properties of drug-like compounds, particularly regarding their
oral bioavailability (Veber et al., 2002). Others have proposed alternative rules such as
those related to the permeability of the blood-brain barrier (Oprea, 2002; Andrew M
Davis et al., 2001; Pardridge, 1995).
The ultimate goal of FBS is to construct inhibitors with KDs in the nanomolar range
from fragment hits. Although fragments tend to bind with KDs in the millimolar range,
they tend to make ‘high quality’ i.e. highly favourable-interactions compared with hits
from HTS (Figure 1.5, 1.6).
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Figure 1.5. The dependency of molecular weight on potency; The improvement of potency is highlighted
in relation to LE. Reproduced from (Scott et al., 2012).

In order to estimate the ‘drug-likeness’ of hit molecules and derivatives, several metrics
are used. Ligand efficiency (LE) and group efficiency (GE) are two examples of such
metrics (Hopkins et al., 2004; Kuntz et al., 1999; Verdonk and Rees, 2008). LE is
defined as -ΔG/HAC, where ΔG is the Gibbs free energy of binding, and HAC is the
heavy (non-hydrogen) atom count. In contrast, GE stresses the relative importance of
functional groups either added to or excluded from a hit molecule during optimisation.
It is expressed as GE = - ΔΔGb/ΔHA: where ΔΔGb = ΔGb(B)-ΔGb(A) and ΔHAC
=HAC(B)-HAC(A), where A and B are the existing and optimised molecules
respectively, and ΔGb(B) and ΔGb(A) are the free energies of binding of existing and
optimised molecules

(Verdonk and Rees, 2008). All of the aforementioned

requirements directly or indirectly influence each other emphasizing the complexity of
the fragment-to-lead optimisation.
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When available, multiple fragment hits in different parts of a target site can be linked to
build lead compounds with higher affinity (Figure 1.6).

Figure 1.6. A comparison of HTS and FBS that visualizes the predicted ligand fitting into the binding
pocket of a target. Figure reproduced from (Scott et al., 2012).

Although HTS has been used successfully against many targets, the hit rate is often very
low. Moreover, the optimisation of large drug-like molecules is challenging. There is a
correlation between molecule size and poor pharmacokinetic properties. With FBS, low
affinity hits are extended gradually, with physical properties carefully controlled, in
order to increase their affinity to the target. The comparison of HTS to FBS is
summarized in Table 1.1 (Rees et al., 2004).

Table 1.1. A comparison of HTS and FBS showing the two main screening approaches. Reproduced from
(Rees et al., 2004).

HTS

FBS

Emphasis on

potency

efficiency

MW range

~250 – 600

~150 - 300

Hit activity range (KD)

~30 μM - nM

~mM – 30 μM

Fragment library can be screened against the target using various biophysical techniques
(X-ray, NMR, SPR) in order to detect non-covalent biding, followed by fragment
elaboration, during which the lead compound will be generated. The entire process is
summarized in Figure 1.7 (Scott et al., 2012).
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Figure 1.7. Highlighting comparative screening methods, showing the fragment-based drug discovery
process. Based on (Scott et al., 2012).

1.4.2 A Fragment-based Screening Methods
The choice of screening method for FBS is crucial. A “three-stage biophysical cascade”
has been proposed as a good fragment screening platform, starting with a preliminary
screen (thermal shift assay), validation (ligand binding observed by NMR) and
structural characterisation (X-ray crystallography) (Mashalidis et al., 2013). The use of
different biophysical methods at different stages of fragment screening helps to validate
the results and eliminate false positives. At present there are only a few methods that
can detect weak protein-fragment and nucleic acid-fragment interactions, e.g., NMR, Xray crystallography, surface plasmon resonance (SPR), fluorescence polarization (FP),
isothermal titration calorimetry (ITC) and more recently mass spectroscopy and thermal
shift assays. A comparison of some of these methods is given in Table 1.2 below. Each
of the approaches mentioned has an associated affinity detection range. FBS typically
begins with small molecules often with KD in the millimolar range (Figure 1.8). Any
method used to screen fragments should be sensitive enough to detect these interactions.
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Figure 1.8. Representation of the affinity range detected by various biophysical methods. Based on
(Hubbard and Murray, 2011).

Subsequent in silico screening tools, such as virtual screening, molecular docking, and
molecular dynamics (MD) simulations are commonly used to extend our knowledge
beyond the available spectroscopic limits.
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Table 1.2. Comparison of screening methods. Table reproduced with some modifications from (Dalvit and Stockman, 2002).

X-ray
crystallography

NMR
Ligand-observed

SPR

ITC

FP

Protein-observed

-

[EL]

[EL]/[ET]

[EL]/[ET]

[EL]/[ET]

[EL]/[ET]

Slow

Fast

Fast

Fast

Slow

Fast

No

No

Yes

Yes

No

Yes

μM to mM

Low μM

μM

μM

μM

Low μM

μM to mM

μM

μM to mM

μM to mM

μM to mM

μM to mM

Yes

No

Yes

No

No

No

Yes

Yes

No

No

No

No

Dynamic range

-

Large

Medium-large

Small

Small

Small

Intrinsic

-

Low

Low

High

High

High

Response
dependence
Data acquisition
Speed
Protein size
sensitivity
Protein
concentration
Fragment
concentration
Binding site on
target
Binding epitope
on ligand

sensitivity
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1.4.2.1 X-ray Crystallography
The information provided by X-ray crystallography is in the form of atomic threedimensional structures of target biomolecules and complexes with ligands. The use of
crystallization robots, synchrotron beam-lines, robotic sample changers, and automated
fitting of electron density by programs such as AutoSolve by Astex Therapeutics (Mooij
et al., 2006) makes crystallography a useful high throughput method for solving the
structures and observing the orientation of ligand in the binding pocket. Required for
FBS by X-ray crystallography are robust crystals amenable to soaking experiments.
Another essential requirement is that in general, the resolution should be greater than
2.5 Å so that ligand-binding poses can be interpreted unambiguously. Also, the target
biding site should be unhindered by crystal contacts (Warren et al., 2012). Crystalizing
the target can be time consuming and challenging, depending on the protein.
Crystallography occasionally yields false positives that can sometimes be explained by
the use of DMSO as a solvent for fragments, and by artefacts arising from
crystallization conditions (such as a conformation of macromolecule dominant in the
crystal form but not highly populated in solution). By X-ray crystallography, only one
single conformation of the ligand and/or macromolecule is typically observed. If
diffraction quality is sufficiently high, it is possible to detect multiple conformers of
protein side chains and/or fragments. The availability of crystal structures of target
proteins makes it possible to apply computational methods such as MD simulations to
study the dynamic behaviour of the complex structure.

1.4.2.2 Nuclear Magnetic Resonance
Nuclear Magnetic Resonance (NMR) is a method extensively used in structural and
chemical biology. Methodological advances have made it possible to apply NMR to
molecules with various NMR-active nuclei (e.g. 1H,

13

C,

15

N,

31

P,

19

F) to study

structures, function and interactions (Grzesiek and Sass, 2009). In 2000, scientists at
Abbott Laboratories used NMR as a fragment screening tool for the first time (Hajduk,
2006). Improvements in technique and increased automation has allowed the detection
of ligand binding in vivo (Betz et al., 2006). From a drug discovery perspective, NMR
experiments can be divided into two groups: protein-based (HSQC, HMQC, TOCSY,
NOESY etc.) and ligand-based methods (STD, CPMG, WaterLOGSY etc.) (Dalvit and
Stockman, 2002). Ligand-based NMR methods were introduced about 15 years ago
12
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(Dalvit et al., 2001; Mayer and Meyer, 1999; Hajduk et al., 1997). They are now widely
used as a primary screening steps. These methods rely on the observation of NMR
signals from ligands. Their advantage is that there is no effective upper limit on the size
of the protein. NMR-based methods can even been applied to screening for ligands that
bind to membrane proteins (Meinecke and Meyer, 2001). Ligand-based methods are
more efficient for larger proteins, which have longer rotational correlation times (τc) and
exhibit a negative Nuclear Overhauser Effect (NOE) that improves spin diffusion and
therefore saturation transfer from protein to bound ligand. Furthermore, protein
consumption is low compare to other biophysical techniques (Dalvit, 2009; Mayer and
Meyer, 1999). Cocktails containing up to 10 fragments each can be screened at once. A
limitation of ligand-based methods is that no structural data is obtained for the binding
location of ligands on the biomolecule. However, it is capable of providing ligand
epitope (Mayer and Meyer, 2001). A useful property of the ligand-based methods is the
ability to detecting weak binding, i.e., KD values of up to 10 mM (Meyer and Peters,
2003). For both STD and waterLOGSY to be successful, the off-rate has to be fast in
relation to the relaxation time. The corresponds to dissociation constants in the mM to
μM range. The smallest dissociation constant reported for waterLOGSY was ~ 0.1 μM
(Dalvit et al., 2001).
Another ligand-based method is Carr-Purcell-Meiboom-Gill (CPMG) NMR. This
method exploits differences in relaxation properties between small molecules and
proteins, and is based on measurements of relaxation properties of small molecules that
differ in the free and bound states. It has the ability to detect tighter binders with KD
values in the nM range (Dalvit and Stockman, 2002).
In the absence of protein crystals, ligand-based methods may be followed by 1H-15N
and/or 1H-13C HSQC experiments in order to identify the residues involved in binding.
1

H-15N HSQC is highly sensitive to weak interactions with KD as high as 10 mM

(Zuiderweg, 2002). These protein-based NMR experiments require isotopically labelled
protein. Despite the limitations noted below, protein-based NMR is useful for proteins
of MW up to 30-35 kDa. Recent developments have made possible the use of NMR for
larger proteins and membrane proteins with size of up to 1,000,000 Da using TROSYbased approaches (Zhu and Yao, 2008; Fernández and Wider, 2003).
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1.4.2.3 Surface Plasmon Resonance
Surface

plasmon

resonance

(SPR)

is

a

method

used

to

kinetically

and

thermodynamically quantify protein-protein, protein-nucleic acid and protein-small
molecule interactions. The sensitivity levels of this technique have improved to the
point that it can be used for fragment screening. SPR measures binding directly and
requires the target protein to be immobilized on the surface of a gold chip. For FBS, a
solution containing fragments is passed over the surface (Danielson, 2009; Neumann et
al., 2007). The physical basis for detecting binding is illustrated in Figure 1.9. The
detection of binding in real time is based on SPR phenomena. Polarized light reflected
off a gold surface is recorded by a detector in real time. Changes in the microenvironment of the gold surface will affect the reflection of light. Some SPR
instruments are sensitive enough to detect binding of weakly interacting fragments
(Dolezal et al., 2013). An SPR-based experiment can provide a kinetic profile of
binding and unbinding events (association ka and dissociation rates kd) (Cooper, 2002).
There are several methods for immobilizing protein on chip surface. Amine coupling is
an example that is based on the formation of amide bonds between the protein and the
chip surface. A potential shortcoming of this method is that the binding site of interest
could be blocked during the immobilization process. An alternative strategy to amine
coupling is to use the streptavidin-biotin interaction. This approach requires the
covalent attachment of biotin at the N- or C-terminus of the protein. The biotinylated
protein will bind to a streptavidin-coated chip surface with high affinity.
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Figure 1.9. Schematic representation of a SPR experiment. (A) is the representation of the chip surface
and (B) is the typical sensorgram corresponding to association/dissociation. Based on(Patching, 2014).

1.4.2.4 Isothermal Titration calorimetry
Isothermal titration calorimetry (ITC) is a valuable tool for measuring binding affinities,
and thermodynamic data; the binding free energy (ΔG), which can be decomposed into
15
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enthalpic and entropic contributions (ΔH and TΔS). When protein interacts with a
ligand heat is either absorbed or released. In ITC, a ligand is injected into a chamber
with the protein of interest, and the resulting change in heat is measured. ITC is able to
measure interaction KDs ranging from mM to nM. This range can be extended to the pM
range using competition assays. Heat changes can result from: ligand and
macromolecule dilution, heat of mixing, buffer mismatch, in addition to the interaction
of interest. The typical ITC instrument comprised of a reference cell and a sample cell.
The temperature is in both chambers is constantly maintained. Heat changes in the
sample chamber is measured relative to reference cell by the instrument (Holdgate and
Ward, 2005).
A disadvantages of ITC is relatively low throughput and high sample consumption. It
can, however, provide, binding stoichiometry as well as the aforementioned
thermodynamic data on the basis of a single experiment (Doyle, 1997).

1.4.3 Fragment Optimisation
Fragment hits must be optimised in order to improve affinity. The common procedures
for fragment optimisation include fragment merging, linking and/or growing (Figure
1.19).
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Figure 1.10. Illustration of fragment optimisation procedures: (a) fragment merging, (b) fragment linking
and (c) fragment growing. Reproduced from (Scott et al., 2012).

The choice of optimisation path depends on the shape of the target binding pocket and
the binding orientation of the fragments. In those instances where the binding pocket
has a larger volume or consist of sub-pockets, a favourable approach may be to link
fragments (assuming that there are fragments identified binding to multiple subpockets). Where pockets are small and narrow, the optimal choice is most likely to be
fragment growth.

1.5 DNA Replication
Every dividing cell must pass on its genetic information by duplicating the genetic
material, i.e. DNA. DNA replication is multi-step dynamic process entailing more than
30 different protein-protein and protein-nucleic acid interactions, the functions of which
are coordinated by forming a large nucleoprotein complex that is known as the
replisome (Schaeffer et al., 2005).
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In E. coli, DNA replication can be reduced to the following steps; (1) initiation, starting
at oriC, the origin of replication, (2) elongation, in which two replication forks proceed
in opposite directions around the chromosome and (3) termination, the step when
replications ceases after replication forks reach a ter site.

1.5.1 The Origin of replication: Initiation
Initiation is the starting point of DNA replication, a process that is subdivided into three
steps: (a) the recognition and unwinding of DNA at oriC, (b) the loading of the
primosomal complex and RNA priming and (c) formation of DNA polymerase
holoenzyme (Pol III HE). In order to initiate DNA replication, double-stranded DNA
(dsDNA) must be unwound to form single-stranded DNA (ssDNA). Initiation begins
with the interaction of DnaA protein with dsDNA at oriC to start the ‘breaking’ of
dsDNA. It creates two divergent bidirectional replication forks at oriC (Baker et al.,
1987).
The DnaB6-DnaC6 hexameric complex encircles ssDNA at oriC (Yuzhakov et al., 1996;
Bárcena et al., 2001; Jezewska et al., 1998). It provides ssDNA template for loading the
DnaG primase to form DnaB6-DnaG3 primosomal complex (Fang et al., 1999).
The final step of initiation includes the formation of Pol III HE assembly. Poll III HE is
a large complex consisting of the clamp loader complex (τ, γ, δ, δ’, χ and ψ subunits),
Pol III catalytic core (α, ε and θ subunits) and sliding clamp (β2) for coordination of
strand synthesis (McHenry and Crow, 1979; McHenry, 2011; O'Donnell and Studwell,
1990; Stukenberg and O’Donnell, 1995). A schematic view of initiation is shown in
Figure 1.11A.
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Figure 1.11. A schematic representation of DNA replication. (A) Steps of initiation and (B) replication
fork. Modified from (Robinson and van Oijen, 2013).

1.5.2 Elongation
Once all necessary components are assembled at oriC, elongation (the synthesis of new
DNA strands) starts. Elongation is a highly synchronized process that involves the
unwinding of dsDNA and the continuous synthesis of the leading and lagging strands.
Due to the antiparallel nature of parental DNA, one strand is synthesized continuously
(the leading strand), the other discontinuously (the lagging strand). The lagging strand is
comprised of so-called “Okazaki fragments” (Okazaki et al., 1967). For the leading
strand synthesis, DnaG primase synthesise the RNA primers, thereafter to be used by
polymerase to synthesise a new strand from the leading strand template (Kohara et al.,
1985). Meanwhile for lagging strand, multiple primers are required for discontinuous
synthesis of Okazaki fragments (McMacken et al., 1977). Primer synthesis requires
contact between the DnaG primase and DnaB helicase (Arai and Kornberg, 1979). The
complete schematic representation of replisome at the replication fork is shown in
Figure 1.11B. For leading strand synthesis to take place, a few priming steps may be
sufficient for continuous strand synthesis to occur. In order for a complete synthesis of
19
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the lagging strand, efficient priming that guarantees the completion of newly
synthesized strand is required. At each step DnaG primase is recycled. Subsequent to
synthesized Okazaki fragment synthesis, Pol I is required to remove the RNA primer
and replace it with DNA, and DNA ligase to join the fragments together. The
mechanism by which primase is recycled has been explained using a three-point switch
model (Yuzhakov et al., 1999). It involves DnaB helicase, DnaG primase, single
stranded DNA-binding protein (SSB), and the χ subunit of Pol III. The SSB coating
ssDNA interacts through its C-terminal region with DnaG primase and Pol III χ subunit
(Shereda et al., 2008). DnaG primase, in turn, is bound to DnaB helicase. DnaG primase
requires SSB-Ct binding to maintain contact with the primed site. Pol III χ displaces
DnaG primase, which can then be recycled. The recycling of DnaG primase is repeated
for each Okazaki fragment.

1.5.3 Termination
The two replication forks eventually meet at the one of the specific replication terminus
(Ter) sites in the chromosome. The Tus protein binds to Ter sites and block replication
forks that approach from non-permissive sides causing termination of replication
(Coskun-Ari et al., 1994; Coskun-Ari and Hill, 1997).

1.5.4 Single Stranded DNA-Binding Protein
SSB is one of the essential components of DNA replication, replication restart,
recombination and DNA repair. It is comprised of oligonucleotide/oligosaccharide
binding (OB) domain (residues 1-114), responsible for binding to the ssDNA and a
flexible C-terminal region (residues 115-177) that terminates with a highly conserved
hexapeptide motif (SSB-Ct; residues 168-177) at the end of the C-terminus (Figure
1.12) (Shereda et al., 2008).

Figure 1.12. Schematic view of E. coli SSB. Dotted lines represent the flexible region. Increasing font
size represents greater degree of conservation of residues among SSB homologs from different species.

SSB is a tetramer in solution. The main function of SSB is to protect ssDNA from
degradation. NMR and X-ray crystal structures demonstrate that in full-length SSB, the
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C-terminal domain including the highly conserved C-terminal motif is disordered
(Shishmarev et al., 2014).
Two DNA-binding modes are identified for ssDNA to SSB: the 35-mode (35 nucleotide
based are wrapped around SSB tetramer) and 65-mode (65 nucleotide residues are
bound to SSB). Each binding mode depends on experimental conditions such as salt
concentration, temperature, pH and protein concentration (Raghunathan et al., 1997).
The crystal structure of E. coli SSB alone and in complex with ssDNA in the (SSB)35
binding mode are is shown in Figure 1.13.

Figure 1.13. Crystal structure of E. coli SSB (A) and with ssDNA in 35 mode (B). Each monomer
represented in different colour. ssDNA is shown in green (PDB ID: 4MZ9 and 1EYG).

The availability of structures of SSB homologues from different species (E. coli, P.
falciparum, M, tuberculosis) allows conserved structural and functional features of
SSB/ssDNA interactions to be identified. Comparison of E. coli and Deinococcus
radiodurans structures supports the overall ssDNA binding mechanism (George et al.,
2012). Plasmodium falciparum is a parasitic protozoan responsible for malaria. P.
falciparum SSB is also a tetramer with different amino acid composition at the Cterminus. The structures of Pf-SSB tetramer and its complex with a ssDNA shows
similarities to E. coli SSB, however, ssDNA wraps around SSB with opposite
handedness to that observed in E. coli (Figure 1.14) (Antony et al., 2012).
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Figure 1.14. Different binding modes of SSB and ssDNA in E. coli and Pf. respectively. Reproduced
from (Antony et al., 2012).

SSB is a protein-interaction hub (Shereda et al., 2008) that interacts with at least 14
proteins. It was shown in some cases that these the interactions occurs via the conserved
C-terminal hexapeptide motif. A list of SSB-Ct binding partners is shown in Table 1.3.
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Table 1.3. SSB-Ct binding partners. Structures of proteins where complexes with SSB-Ct have been determined are indicated (*).

Protein
χ subunit of

SSB-Ct

Binding

required?

affinity KD

Yes

9 μM

Function

References

Part of clamp loader complex

(Kelman et al., 1998; Yuzhakov et al., 1999; Witte et al., 2003; Butland et
al., 2005)

DNA Pol III)*
DnaG*

Yes

2 μM

RNA primers synthesis

(Yuzhakov et al., 1999)

ExoI*

Yes

136 nM

Methyl directed mismatch repair

(Molineux and Gefter, 1974; Butland et al., 2005; Lu and Keck, 2008)

ExoIX

Unknown

-

Phospodiester backbone cleavage

(Hodskinson et al., 2007)

PriA*

Yes

2 μM

Replication restart

(Cadman and McGlynn, 2004; Butland et al., 2005; Lecointe et al., 2007)

PriB

Unknown

-

Replication restart

(Low et al., 1982)

RecG

Yes

n.d.

Replication and repair

(Butland et al., 2005; Lecointe et al., 2007; Buss et al., 2008)

RecJ

Unknown

-

Replication and repair

(Butland et al., 2005; Han et al., 2006)

RecO*

Yes

60 nM

Recombination

(Umezu and Kolodner, 1994; Ryzhikov et al., 2011)

Yes

6 μM

Replication and repair

(Butland et al., 2005; Lecointe et al., 2007; Shereda et al., 2007; Shereda et

RecQ

al., 2009)

Topoisomerase III

Unknown

DNA Pol II

-

Replication and repair

(Butland et al., 2005)

Yes

Replication and repair

(Molineux and Gefter, 1974)

DNA Pol V

Yes

Replication and repair

(Arad et al., 2008)

UDG*

Yes

Replication and repair

(Purnapatre et al., 1999; Handa et al., 2001)

DNA Pol IV

Yes

DNA strain relaxation during the unwinding

(Furukohri et al., 2012)

1.7 nM
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The numerous essential interactions SSB-Ct makes with other proteins, makes is a
potential drug target. Furthermore, the human SSB C-terminus is distinctive and
therefore inhibitors of bacterial SSB-Ct interactions are unlikely to react with human
SSB-Ct-binding partners (Robinson et al., 2010).

1.5.5 DnaG primase
DnaG primase is a DNA-dependent RNA polymerase encoded by the dnaG gene
(Bouché et al., 1975). The E. coli protein consist of 581 amino acids (65.5 kDa) with
three distinct domains (Figure 1.15): an N-terminal zinc-binding domain (ZBD,
residues 1-110); the central domain RNA polymerase domain (RPD, residues 111-433);
and the C-terminal helicase-binding domain (HBD, DnaGC, residues 434-581).

Figure 1.15. Schematic view of E. coli DnaG primase. Each domain is shown in a different colour.

The structure of all three domains in isolation have been determined. The structure of
the ZBD of DnaG primase from B. stearothermophilus was solved by X-ray
crystallography (Pan and Wigley, 2000). The zinc-binding motif contains conserved
Cys-His-Cys-Cys motif responsible for coordinating a Zn2+ ion (Berg, 1990). The ZBD
is responsible for binding to DNA templates, specifically short nucleotide sequences
[5’-C(A/T)G-3’]. Once the contact is established with ssDNA, the RPD domain binds
and synthesizes RNA primers (Kusakabe and Richardson, 1996; Anon, 2000) (Figure
1.16).

Figure 1.16. Crystal structure of E. coli RPD domain of DnaG primase (PDB ID:1DD9) (Keck et al.,
2000). Grey, red and yellow colour of the DnaG-RNAP domain correspond to N-terminal (residues 115 to
240), central (residues 241 to 367), and C-terminal (residues 368 to 428) segments. Residue Q265 is
coloured blue and the Asp-X-Asp residues are coloured green.
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The catalytic core of DnaG has a conserved stretch of ~80 residues (within the central
domain; residues 259-341) identified in type IA and II topoisomerases and in DnaGtype primases in archaea and bacteria, called a TOPRIM (topoisomerase/primase) subdomain found in the central segment of RPD (Figure 1.16). There are only five
conserved residues in all of these three types of proteins. In E. coli, two of them are
glycine residues and the other three are acidic residues (Glu265, Asp309 and Asp311).
Both types of topoisomerases have a conserved tyrosine residue in their TOPRIM
domains responsible for binding DNA that is missing in the primase. Primase contains a
tyrosine residue (Tyr197) with an equivalent function that is not contained in its
TOPRIM domain lying in a position equivalent to the aforementioned tyrosine residue
in the topoisomerases to bind to the DNA. TOPRIM domains have two conserved acidic
motifs (Glu265 and residues 309-311 in E. coli DnaG) (Figure 1.16). It has been shown
that an essential conserved motif is required for Mg2+ mediated NTP-binding (Aravind
et al., 1998; Keck and Berger, 2000; Podobnik et al., 2000).
DnaG primase interacts with DnaB helicase (Bailey et al., 2007; Loscha et al., 2004)
and SSB (Yuzhakov et al., 1999; Naue et al., 2013) through its C-terminal domain
(DnaGC). DnaGC is a monomer in solution (Oakley et al., 2005). The structure of E.
coli DnaGC was previously determined by X-ray crystallography at 2.8 Ȧ resolution
and NMR spectroscopy (Figure 1.17) (Loscha et al., 2004).

Figure 1.17. (A) Crystal structure of DnaGC (PDB ID: 1T3W) (Oakley et al., 2005). Ribbon
representation of two molecules in the asymmetric unit. Each monomer is shown in a different colour
(green and magenta). (B) NMR structure of DnaGC (PDB ID: 2HAJ) (Su et al., 2006). The 20 lowest
energy conformations are shown.
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The crystal structure contained two monomers in the asymmetric unit that form a
domain-swapped dimer (Figure 1.17A). The first 14 residues of the construct (residues
429 to 443) were not observed in the crystal structure and were furthermore observed to
be flexible by the NMR (Loscha et al., 2004; Su et al., 2006). A recent crystal structure
of the complex between the hexameric DnaB and the DnaG primase of G.
stearothermophilus was solved by X-ray crystallography (Figure 1.18) (Bailey et al.,
2007). The crystal structure showed that DnaB interacts with DnaGC forming stable
two-layered ring structure, interacting through DnaGCs C-terminal helix.

Figure 1.18. Structure of the complex of hexameric DnaB helicase and the HBD of DnaG from G.
stearothermophilus (PDB ID: 2R6A) (Bailey et al., 2007). (A) Cartoon representation of the structure
from the top with three monomers of DnaGC (yellow) biding to the N-terminal domain (green) Cterminal domain (magenta) of hexameric DnaB helicase, (B) Surface representation of the structure from
the side with same colour representation as in (A).

The stoichiometry and binding affinity of the DnaB-DnaG interaction was measured by
SPR (Oakley et al., 2005), and confirmed by the crystal structure of the primosome
complex from G. stearothermophilus. The interaction of three DnaGC molecues with
hexameric DnaB helicase may increase the processivity of replication (Bailey et al.,
2007). Modelling suggests that E. coli DnaG/DnaB interactions are similar (Loscha et
al., 2004; Tak Lo, 2012).
Recently, the structure of the complex of DnaGC with the SSB-Ct peptide was
determined (Tak Lo, 2012). The crystal structure of chimeric DnaGC-linker-SSB-Ct
construct was solved at 1.5 Å resolution, providing insight into the key interactions
between SSB-Ct and DnaGC. The SSB-Ct peptide interacts with the helical bundle subdomain of DnaGC. A binding pocket comprised of Leu446, Met451, Ile455, Pro480,
Leu484, Thr515 and Leu519 residues, forming a hydrophobic cavity to accommodate
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the last 3 residues of SSB-Ct peptide (Ile175, Pro176 and Phe177) (Tak Lo, 2012)
(Figure 1.19).

Figure 1.19. Crystal structure of DnaGC-SSB-Ct chimera. DnaGC is shown with a yellow surface with
the SSB-Ct binding pocket in green. SSB-Ct peptide is represented in sticks. Key residues forming the
pocket is shown in right (Tak Lo, 2012).

Comparison of the SSB-Ct-binding pocket on DnaGC with that of other SSB-binding
proteins highlights some similarities among the SSB-Ct binding partners. The last
residue of the SSB-Ct (Phe177) is buried in the pocket, forming hydrophobic contact
The carboxylic acid group is involved in electrostatic and hydrogen bond interactions
with the DnaGC pocket, most of these with the Arg452 guanidinium group.
Mutagenesis studies carried out simultaneously by two different groups confirm that
some of the residues in the pocket contribute to binding, as demonstrated by K447A,
T450A, R452A and K518A mutants that show severely attenuated binding (Naue et al.,
2013; Tak Lo, 2012). Work published recently has confirmed the location of the binding
pocket of SSB-Ct peptide on DnaGC using NMR (Naue et al., 2013). The perturbed
residues of DnaGC in 15N-HSQC spectra upon titration of SSB-Ct peptide were mapped
onto protein surface, identifying the SSB-Ct binding pocket (Figure 1.20).
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Figure 1.20. Binding surface identified by NMR titration of SSB-Ct peptide into 15N-labelled DnaGC.
Protein is coloured according to their chemical shift magnitude upon addition of peptide. Blue represents
no chemical shifts, red is highest chemical shift observed. Residues forming the SSB-Ct binding pocket
are in stick representation. Reproduced from (Naue et al., 2013).

1.6 Scope of this work
The inhibition of SSB-Ct-binding activity could be used to treat pathogenic bacteria
resistant to currently available antibacterials (Robinson et al., 2010). This thesis
considers the interactions of SSB and its binding partner interactions. MD simulations
were conducted in order to understand the dynamic behaviour of SSB-Ct in complex
with its binding partners using currently available crystal structures of SSB-Ct
complexes (DnaGC, pol III χ, RecO and ExoI) (Chapter 3).
Fragment-based screening against DnaG primase was carried out (Chapter 4). The first
generation of hits identified by SPR and STD experiments were further characterised by
protein-based NMR approaches (Chapter 5). In silico hit-to-lead optimisation was
carried out (Chapter 6). Finally, the first generation of optimised hits were tested
against other SSB-Ct binding partners.

28

Chapter 2
Material and Methods

Chapter 2: Material and Methods

2.1 MATERIALS
2.1.1 E. coli Strains and Plasmid Vectors
Plasmids (PKL1176) encoding E. coli DnaGC and RCD proteins (Figure 2.1) were
described previously (Loscha et al., 2004; Tak Lo, 2012). The E. coli BL21(λDE3)recA
strain was used as an expression host for the overproduction of DnaGC and RCD
proteins (Loscha et al., 2004).

Figure 2.1. Schematic diagram of DnaGC and RCD plasmids (Loscha et al., 2004; Tak Lo, 2012).

2.1.2 Growth Media
2.1.2.1 LB Liquid Medium
Lysogeny broth (LB) media (25 g/L) (Moore and Brubaker, 1975) supplemented with
25 mg/L thymine and 100 mg/L Ampicillin was used for growth of E. coli strains.
Media was autoclaved prior to addition of antibiotic before inoculation with bacteria.
Overnight cultures (5 mL) were used to inoculate fresh LB cultures (1 L) for
overproduction of protein. E. coli strains with λ vectors were grown at 30 °C with
shaking at ~260 rpm using an orbital shaker. Overnight growth (~18 h inoculation) was
used.

2.1.2.2 LB Solid Medium
Cells containing targeting vectors were grown on LB agar plates (15 g/L agar in LB
media with appropriate antibiotic) in an incubator at 30 °C overnight (~ 18 h).
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2.1.3 Custom Peptides
Peptides for fluorescence polarization assays were obtained from Mimotopes (Clayton,
VIC). Peptides were labelled with fluorescein at their N-termini. Prior to use, peptides
were dissolved in 100% DMSO and stored at -20 °C.
N-terminally biotinylated SSB-Ct peptide [Biotin-(Ahx)-GSAPSNEPPMDFDDDIPF;
where Ahx an amino-hexanoate spacer, is followed by 16 C-terminal residues of SSB
highlighted in bold] was synthesized at Biomolecular Resource Facility at the John
Curtin School of Medical Research, ANU. The peptide was dissolved in water and
stored at -20 °C.

2.1.4 Protein purification components
2.1.4.1 15N-labelledMinimal Media
Minimal media contained

15

N-labelled ammonium chloride, thymine, glucose, solution

of trace metals and basic salt solution. The full recipe for minimal media is shown in
Table 2.1.
Table 2.1. Composition of minimal media.

20 × Basic salt solution

Per 0.5 L

NaH2PO4 × 2H2O (pH 7.0)

61 g

K2HPO4

106 g

1000 × Trace metal solution

Per 100 mL

MQW

36 mL

0.1M FeCl3 in 0.1 M HCl

50 mL

1 M CaCl2

2 mL

0.1 M Na2SeO3

2 mL

0.1 M H3BO4

2 mL

1 M MnCl2

1 mL

1 M ZnSO4

1 mL

0.2 M CoCl2

1 mL

0.1 M CuCl2

2 mL

0.2 M NiCl2

1 mL

0.1 M NaMoO2

2 mL
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The mixture of 50 mL of 20 × basic salt solution with 1 g/L 15NH4Cl in 1L water was
autoclaved. Prior to inoculation of 1L culture, 1 mL of 1 M MgSO4 with 1 mL of metal
mix and 3 g of D-(+) glucose with 100 μL of 10 g/L thymine was added before
transferring to 30 °C in presence of 100 μg/mL Ampicillin.

2.1.4.2 Buffers for Protein Purification
Buffers used for purification of RCD and DnaGC were: lysis buffer [50 mM Tris-HCl
(pH 7.6), 1 mM EDTA, 1 mM DTT, 10% (w/v) sucrose, 150 mM NaCl, 10 mM
spermidine]; Buffer A [50 mM Tris-HCl (pH 7.6), 1 mM EDTA, 1 mM DTT]; and
Buffer B [50 mM Tris-HCl (pH 7.6), 1 mM EDTA, 2 M NaCl and 1 mM DTT].

2.1.5 Fragment library
The “first pass screen” fragment library (Zenobia Therapeutics) was used for the SPR
competition assay. For storage, stocks for each fragment were made by addition of 50
μL DMSO to each fragment (200 mM final concentration). Each fragment was diluted
with DMSO to 1 mM final concentration for the competition assay. The compounds
were assayed for chip surface binding in order to eliminate false positives.
The MIPS fragment library was used for STD NMR experiments. It comprised of
around 1140 fragments. The individual fragments were diluted in 2H6-DMSO to give
~660 mM final stock concentration (Doak et al., 2013).
The fragments were mixed in cocktails of up to 6 compounds and had well-resolved
resonances in their 1D 1H NMR spectra. Fragment cocktails were generated such that
overlaps in their 1D 1H NMR spectra were avoided.

2.2 METHODS
2.2.1 General Protein Biochemistry Methods
2.2.1.1 Dialysis of Protein
Dialysis was used for protein buffer exchange during the purification steps and prior to
other experiments. Spectra/Por standard regenerated cellulose dialysis membranes
(spectrum Laboratories, Rancho Dominguez, CA, USA) were used for protein dialysis.
An appropriate molecular weight cut-off was selected for each protein to be smaller
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than molecular weight of the target protein. Three changes of new buffer were
performed each one at least 3 h duration at 4 °C.

2.2.1.2 Fast Protein Liquid Chromatography Purification of Protein
Overexpressed proteins were purified by DEAE, MonoQ ion exchange columns using
the ÄKTA™ system (ÄKTApurifier™ or ÄKTAFPLC™) instrument equipped with
fraction collector (Frac-9500 or Frac-920), controlled by UNICORN™ software (GE
Healthcare). Protein elution was assayed continuously by protein absorbance at λ = 280
nm and conductivity. All protein purification steps were carried out at 4 °C.

2.2.1.3 Denaturing Sodium Dodecyl Sulphate Polyacrylamide Gel
Electrophoresis
Protein purity was assessed using sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE). Pre-cast gels (4-12%) (Bio-Rad, NSW Australia) were
used in all experiments. Protein molecular weight markers were obtained from Bio-Rad
(Precision Plus ProteinTM Dual Colour standards). Protein samples were mixed with
equal volume of the dye [300 mM Tris base, 15% (v/v) glycerol, 0.6% (w/v)
bromophenol blue, 200 mM DTT, 1% SDS]. Samples were loaded onto gels, and 180200 V was applied until the bromophenol blue dye had reached the end of the gel. Gels
were then washed with water and stained by adding staining solution [0.2% (w/v)
Coomassie brilliant blue R, 40% (v/v) methanol and 10% (v/v) acetic acid] with heating
in a microwave over for 1 minute (until boiling) and gently shaken for ~15 min. Gels
were destained [40% (v/v) isopropanol, 10% (v/v) acetic acid] until the background
colour was gone.

2.2.1.4 Determination of Protein Concentration
Protein UV absorbance at 280 nm wavelength (A280) was used to determine protein
concentration in solution using NanoDrop 2000c™ (Thermo Scientific). The proteins
extinction coefficient at 280 nm (ε280) was calculated by ExPASy Server using the
number of tryptophan and tyrosine amino acids in the protein sequence (Gasteiger et al.,
2005).
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2.2.1.5 Concentration of Protein: Ultrafiltration
Protein solutions were concentrated using Amicon Ultra-4 centrifuge filters with 3 kDa
molecular weight cut-off (Millipore, Bedford, USA). Prior to use, membranes of the
filters were rinsed twice with Milli-Q water to remove preservative (glycerol). Solutions
were centrifuged for 15 min at 4000 × g in a Sorvall® Super T21 Benchtop Super speed
Centrifuge (Thermo Scientific, Waltham, MA) using a ST-H750 rotor. Following each
centrifugation step, samples were thoroughly mixed by repeated pipetting to prevent
protein aggregation.

2.2.1.6 Electrospray Ionization Mass Spectrometry (ESI-MS)
The molecular weight of purified protein was confirmed using ESI-MS that gives the
molecular mass of protein to 0.01% precision. Mass spectra were acquired using
quadrupole-time-of-flight (Q-TOF) Ultima™ mass spectrometer equipped with Z-spray
probe and mass analyzer with 32,000 m/z range. The instrument was controlled using
MassLynx 4.1 software (Micromass, UK), and calibrated using cesium iodide (10
mg/mL in 70% isopropanol). The protein concentration required for measurements was
~10 μM. Proteins were dialyzed against 0.1% of formic acid prior to analysis.

2.2.1.7 Expression and Purification of the RCD and DnaGC domains
The RCD overproduction and purification protocol was essentially the same as
unlebelled DnaGC described previously (Loscha et al., 2004). Plasmid pKL1176
containing gene encoding the RCD domain was transformed into E. coli
BL21(λDE3)recA cells (Williams, 2002). Cells were grown in 1 L cultures in LB broth
in the presence of 100 μg/mL Ampicillin at 30 °C until OD600 reached ~0.6. The
temperature was rapidly shifted to 42 °C by transfer of flasks to a heated incubator, and
the cultures shaken for another 3 h. Cells were harvested by centrifugation (11,000 × g,
15 min), the cell pellet was resuspended in lysis buffer (15 mL lysis buffer per 1 g of
cells). Cells were lysed by passing the cell suspension through a French press. After
centrifugation (10,000 × g, 90 min), 0.3 g/mL (NH4)2SO4 was used to precipitate the
proteins from the supernatant, followed by dialysis against 2 L of buffer A with 100
mM NaCl, changed twice. The protein was passed twice though a DEAE column
(DEAE-650M resin), first in the presence of buffer A with 100 mM NaCl, and second in
buffer A without NaCl. A third anion exchange step utilized a Mono QTM column
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(10/100 GL column 8 mL: 10 × 100 mm: GE Healthcare) with the same buffer
conditions (buffer A without NaCl) followed by gel filtration (Superdex 75; GE
Healthcare) using the buffer A with 100 mM NaCl. Samples were clarified by
centrifugation (40,000 × g, 15 min) prior loading onto columns.
The overproduction of 15N-labelled DnaGC in 15N-rich minimal media was as described
for unlabelled DnaGC/RCD protein.
Cysteine mutants of DnaGC were made by Dr. Zhi-Qiang Xu. Cysteine mutants of 15Nlabelled DnaGC were expressed and purified as described above for

15

N-labelled

DnaGC.

2.2.2 Computational Chemistry Methods
2.2.2.1 System Preparation
Starting coordinates for MD simulations were derived from crystal structures of
DnaGC/SSB-Ct complex at 1.5 Å resolution (Tak Lo, 2012), the RecO/SSB-Ct complex
at 2.3 Å resolution (PDB ID: 3Q8D) (Ryzhikov et al., 2011), the ExoI/SSB-Ct complex
at 2.7 Å resolution (PDB ID: 3C94) (Lu and Keck, 2008) and the χ/ψ-SSB-Ct complex
at 1.85 Å resolution, where the SSB-Ct peptide was modified to WDIPF (PDB ID:
3SXU) (Marceau et al., 2011).
Where multiple molecules were found in the asymmetric unit, only the first was used.
For all available structures, the SSB-Ct peptide was extended where necessary by
manually model building in COOT (Emsley and Cowtan, 2004) to include the last 9
residues of that protein, i.e. MDFDDDIPF. All water molecules were removed.
Hydrogen atoms were built using the PSFGEN plugin in VMD (Humphrey et al., 1996).
Histidine protonation states were assigned based on visual inspection of their hydrogenbonding environments. In all systems the CHARMM27 protein force field was used
(MacKerell et al., 1998; Mackerell et al., 2004). Water molecules (TIP3P) were placed
around protein models so as to create rectangular boxes (Jorgensen et al., 1983). In all
cases there was a minimum distance of 7 Å between protein and the edge of the box.
Sodium and chloride ions were added to ensure that the systems had no net charge. Four
systems: DnaGC/SSB-Ct (~7,700 atoms), RecO/SSB-Ct (~22,500 atoms), ExoI/SSB-Ct
(~42,500 atoms) and χ/ψ–SSB-Ct (~28,200 atoms) were thus generated (Figure 2.2).
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Figure 2.2. Systems od SSB-binding partners: DnaGC (A), RecO (B), ExoI (C) and χ/ψ (D) in water box
in presence of sodium (magenta) and chloride (green) ions.

2.2.2.2 Molecular Dynamics Simulations Protocol
Before starting the MD simulations, the systems were subject to energy minimization
for 10,000 steps. Constant temperature (310 K) was maintained using Langevin
dynamics (Izaguirre et al., 2001; Bussi and Parrinello, 2007) with a 5 ps-1 damping
constant applied to non-hydrogen atoms. Periodic boundary conditions were used with
the Nosé-Hoover Langevin piston pressure control method (Feller et al., 1995) with 100
fs piston period and 50 fs decay rate, respectively, to maintain a constant pressure of
1.013 Bar. The Particle-mesh Ewald (PME) (grid resolution < 1 Å) was used to account
for long-range electrostatic interactions. All other non-bonded interactions were
calculated using switching function to smooth interaction energies to zero between 10
and 12 Å. Coordinates were saved every 1 ps for analysis. All MD trajectories were
calculated using NAMD 2.9 (Phillips et al., 2005). Trajectory data were analysed using
VMD (Humphrey et al., 1996) and customized scripts.
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2.2.2.3 Trajectory Analysis
In silico mutations of the SSB-Ct (Ile175Leu (DDDLPF) and Asp172Asn, Asp173Asn,
Asp174Asn (NNNIPF) were generated using VMD Mutator Plugin (Humphrey et al.,
1996).
As measure of the stability of proteins the radius of gyration (r2gyr) was calculated
according to:
2
𝑟𝑔𝑦𝑟
(𝑡) =

Σ𝑤𝑖 (𝑟𝑖 −𝑟̅𝑖 )2

Eq. 2.1

Σ𝑤𝑖

Where ri is the position of i atom from the center of mass.

Hydrogen bonds were analyzed as follows: A hydrogen bond between a donor and an
acceptor was considered to exist if the relevant groups satisfied distance (< 3.5 Å) and
angle (< 20°) cut-offs. Salt bridges were analysed using the same distance cut-off. These
analyses utilized the Hydrogen Bonds and Salt Bridges Plugins in VMD.
VMD Volmap plugin was used to generate weighted atomic density map of SSB-Ct
peptide in all simulations (Humphrey et al., 1996). The system of interest is divided into
three-dimensional grid (spacing: 1 Å). At each grid point and time-point the atomic
density is calculated by replacing each atom with a normalised Gaussian distribution,
with 1 standard deviation being equal to its atomic radius. It is used to present each
atomic centre and its contribution to atomic density.
The PME algorithm was used in order to calculate long-range electrostatics of the
systems (Darden et al., 1993). The ensemble averaged electrostatics calculations were
carried out using PME Electrostatic plugin in VMD (Aksimentiev and Schulten, 2005).
The clustering analysis was carried out using the Clustering tool plugin in VMD (Luis
Gracia, unpublished program). Clusters of SSB-Ct peptide were generated with 3 Å
RMSD cut-off within clusters.

2.2.3 Surface plasmon resonance competition assay
SPR measurements utilized a Biacore T200 instrument (GE Healthcare) at 20 °C to
measure the competition of compounds for the DnaG/SSB-Ct peptide interaction. The
buffer contained 10 mM HEPES (pH 7.4), 3 mM EDTA, 100 mM NaCl, 2% (v/v)
DMSO, 1 mM DTT and 0.05% (v/v) P20 surfactant (GE Healthcare).
The SSB-Ct peptide immobilization onto the streptavidin chip surface was achieved by
gradually increasing the concentration and injection time of N-terminally biotinylated
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SSB-Ct peptide [Biotin-(Ahx)-GSAPSNEPPMDFDDDIPF; where Ahx an aminohexanoate spacer followed by 16 C-terminal residues of SSB highlighted in bold] to
obtain the highest level of immobilization.
The fragments were mixed with the RCD to bring the final concentration of RCD and
fragment to 30 μM and 1 mM respectively. Each sample was mixed for approximately
15 min prior to measurements. Mixtures were injected separately to flow cells 1 and 2.
Flow cell 1 served as a reference. A flow rate of 5 μL min-1 was used during the 60 s
injection and 60 s dissociation phases. All experiments were conducted at 20 °C.

2.2.4 NMR Spectroscopy
2.2.4.1 Reference spectra
1D 1H NMR spectra for each individual compound in the absence of protein (1 mM in
50 mM phosphate buffer (pH 7.0), 100% 2H2O) were collected at 10 °C on a BrukerBiospin Avance 600 MHz spectrometer with a cryo-probe and auto sample changer
(Bruker-Biospin, Billercia, MA).

2.2.4.2 Saturation transfer difference NMR
STD-NMR experiments to screen fragment libraries were performed in standard NMR
tubes using 5 μM unlabelled protein and fragment cocktails in each sample with a
concentration of ~ 250 μM for each fragment. The sample volume was 500 μL with
100% 2H2O buffer containing 50 mM phosphate buffer pH (7.8), 50 mM NaCl and 1
mM DTT.
STD-NMR experiments were carried out at 10 °C on 600 MHz Bruker Biospin Avance
spectrometer. Saturation of protein was achieved by a 4 s Gaussian pulse sequence train
centered at -1 ppm. For reference spectra, a similar saturation pulse was applied 20,000
Hz off-resonance. A 20 ms spin-lock period was applied before acquisition to allow the
residual protein signals to decay. The STD dataset were acquired over 64 scans. All
NMR data were processed by TOPSPIN 3.1 (Bruker Biospin).

2.2.4.3 2D 1H-15N HSQC NMR
The compounds identified by the SPR and STD screens as hits were confirmed and their
binding sites identified by recording 15N-HQSC experiments on uniformly 15N-labelled
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DnaGC (100 μM) in the presence of compounds at 3.3 mM dissolved in 2H6-DMSO
with 50 mM MES (pH 6.0), 60 mM NaCl, 1mM DTT and 3% 2H2O in a final volume of
150 μL. The acquisition time was 30 min for each 1H-15N HSQC experiment with 12
scans. A standard pulse sequence was used for data acquisition. Spectra were recorded
at 298 K on a Bruker Avance 600 MHz spectrometer (Bruker-Biospin) equipped with
cryoprobe and sample autochanger. The 1H-15N HQSC spectra were processed with
TOPSIN 3.2 and analysed using the CCPN suite (Vranken et al., 2005). Compounds
were regarded as hits if chemical shift perturbations were observed in the HSQC spectra
upon addition of the compound.

2.2.4.4 Chemical Shift Perturbation Calculation
Weighted-average chemical shift perturbation (CSP) was calculated according to Eq.
2.2 (Hajduk et al., 2000).
Δδ=√[δ(1H)complex – δ(1H)free)2 +0.04(δ(15N)complex –δ(15N)free)2]

Eq. 2.2.

Some minor errors were introduced during peak positioning where peaks in the HSQC
were close. These were adjusted manually.

2.2.4.5 Ranking of HSQC Hits
In order to identify the most potent hit compounds in the screen, the hits need to be
ranked based on the magnitudes of the chemical shift perturbations. A compound was
considered a hit if there was a peak movement, and in cases where the peak shifts were
small, the fragment was ranked 1 (weak binder), if the shift was obvious but still within
overlap distance of the equivalent apo-protein peak, the hits were ranked 2 (moderate
binder), and finally if the peak was shifted away the equivalent apo-protein peak with
no overlap, the compound was grouped as rank 3 (strong binder). The disappearance of
peaks identifies a compound as being in intermediate exchange (rank 4: strong hit in
intermediate exchange).

2.2.4.6 1D 19F NMR Experiments
1D

19

F spectra were recorded on a Bruker Avance III 400 MHz NMR spectrometer

equipped with the two-channel BBO probe with z-gradient, at standard 300 K sample
temperature. All 1D 19F spectra were recorded with 256 scans for fragment and complex
samples respectively. Fragment dissolved in 2H6-DMSO were diluted in HSQC buffer
to give final fragment and protein concentration of 1 mM and 50 μM respectively.
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2.2.4.7 KD and LE Measurements
Binding affinities were estimated by incremental titration of compounds into protein,
and recording 1H-15N HSQC experiments at each concentration point. Compound
solubilities were tested to determine the highest concentrations of ligands to be used in
assays. Equilibrium dissociation constants from NMR titration data were derived using
the “single site specific binding with ligand depletion” model in GraphPad Prism 6.0
(Eq. 2.3)
Δδ=Δδmax/2(1+[L0]/[P0]+KD/[P0]-√1+[L0]/[P0]+KD/[P0]2)-4[L0]/[P0]

Eq. 2.3

Where the [L0] and [P0] are total ligand and protein concentrations, Δδmax is the
maximum chemical shift difference observed.
The ligand efficiency was calculated using Eq. 2.4:
LE = ΔG/HAC = -RTlnKD/HAC

Eq. 2.4

Where ΔG is the Gibbs free energy, HAC is the number of heavy (non-hydrogen)
atoms, R is the universal gas constant, T is absolute temperature and KD is equilibrium
dissociation constant.

2.2.4.8 NMR Guided Molecular Docking
NMR data were used to obtaining constraints for docking, using the simple linear
relationship considering between the magnitude of the CSP and the distance from the
amino acid backbone amide atoms and the nearest ligand atom according to protocol
described by Stark et al. (Stark and Robert Powers, 2008). AutoDock Tools 1.5.6 (Trott
and Olson, 2010) was used to prepare protein and ligand structures. The protonation
state of the titratable groups in the protein were assigned at pH 7.0 using PROPKA 3.1
(http://propka.ki.ku.dk) (Li et al., 2005). Polar hydrogen atoms and atom based
Gasteiger partial charges were added. Nonpolar hydrogen atoms were merged with the
parent atom. The protein structure was taken from previously solved crystal structure of
DnaGC with SSB-Ct peptide (Tak Lo, 2012), where protein was treated as rigid body.
The docking calculations were performed using AutoDock Vina 1.1.2 (Trott and Olson,
2010). The calculations were done with an “exhaustiveness” of 1024 with a grid points
separated by 1.0 Å, and a grid size of 16 × 16 × 14 Å. The ligand-binding residues
(those with CSP greater than 0.02 ppm upon fragment binding) were used to generate
parameters for NMR-based constrained docking. Constraints were added in these
perturbed parts of the protein to identify the most likely binding site for hits (Stark and
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Robert Powers, 2008). The grid box was large enough to include the SSB-Ct binding
site. Vina generates low-energy binding poses by evaluating the combined energetic
contributions of torsion, steric repulsion, hydrogen bonding, and hydrophobic
interactions between ligand and protein binding pocket. Ligand data were obtained from
the ZINC database in mol2 format (Irwin and Shoichet, 2005).

2.2.4.9 3D 15N-NOESY-HSQC
15

N-labelled DnaGC with and without compound was used to record 3D

15

N-NOESY-

HSQC (τm 150 ms) experiment in 5 mm Shigemi tube in the HSQC buffer at 298 K.
440 μM

15

N-labelled DnaGC and 1 mM compound was used. Data collection was

performed on Bruker 800 MHz spectrometer with cryoprobe.

2.2.4.10 Paramagnetic Sample Preparation and NMR Recording
In order to maintain the solvent accessible cysteine residues in the mutant proteins the
samples were treated with a five-fold excess of DTT. The excess of DTT was removed
by diluting the sample with NMR buffer and re-concentrating it using Amicon Ultra-4
centrifuge filter with 3 kDa cut-off. The protein was added to a 5-fold excess of aqueous
solution of tag in NMR buffer and incubated overnight at room temperature. The excess
tag was washed out as described above for excess DTT, and the final sample was
transferred to 3 mm Shigemi tube for HSQC acquisition. 1D proton spectrum was
recorded for the compound in presence of paramagnetically tagged protein at 1:4 protein
ligand ratio. All PCS measurements were done on a Bruker 800 MHz spectrometer
equipped with a cryoprobe.
The S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate
(MTSL) nitroxide spin label was attached to Q445C DnaGC first by remove the DTT as
described above, and mixing with 30 equivalents of MTSL dissolved in acetone and
incubating for overnight at room temperature. No precipitation was observed in the
sample, and excess of MTSL was removed as previously described for the lanthanide
tags. The buffer was the same as used in the HSQC NMR experiments. For recording
1D 1H experiments with 1:4 and 1:6 protein-CDS001350 compound, a molar ratio was
recorded for 512 scans. 500 mM ascorbic acid was used as reducing agent from the
paramagnetic to diamagnetic state [(1-acetyl-2, 2, 5, 5-tetramethyl-3-pyrroline-3methyl)-methanethiosulfonate] (MTS) for recording the experiment for diamagnetic
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reference. Samples were kept at room temperature for an hour for complete reaction.
PRE data acquisition was done on Bruker 600 MHz spectrometer with cryoprobe.

2.2.5 Crystallography
Previously published crystallisation conditions for DnaGC [50 mM sodium acetate
buffer (pH 4.6), 2.5% PEG 4000, 100 mM (NH4)2SO4] (Oakley et al., 2005; Loscha et
al., 2004), E. coli χ [100 mM NaOAc, 25% (w/v) PEG 4000, 8% (v/v) isopropanol]
(Tak Lo, 2012) were used in an attempt to reproduce the high quality crystals for
screening. Crystallisation screens were conducted for RCD (JCSG+, PEG, PEG II,
PACT) (Newman et al., 2005; Krosky et al., 2006) varying the protein concentration at
4 °C and 22 °C.
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3.1. Introduction
Molecular dynamic (MD) simulations are widely used in computational chemistry. The
method is based on the calculation of the physical forces between atoms and molecules
using empirical force fields and finite-difference methods to solve the equations of
motion. MD simulations create snapshots of molecular structures as a function of time
known as trajectories (Klepeis et al., 2009). Insights can be gained into the mechanisms
and behaviours of proteins, nucleic acids, and their complexes in atomic detail (Shaw et
al., 2010). The use of MD simulations can lead to new hypotheses concerning
molecular function and advance experimental design.
MD simulations are based on the use of Newton’s Second Law of motion to calculate
the atomic movements. Therefore, atomic masses and a mechanism for calculating the
forces on atoms are required. The latter are described by an appropriate empirical force
field (Eq. 3.1).

Eq. 3.1. Empirical equation for the total energy of a chemical system. Forces can be divided into bonded
and non-bonded terms. Modified from (Durrant and McCammon, 2011). The terms r, θ and ϕ refer to
bond length, angle, dihedral angles Rij is a distance between i and j atoms.

In biochemistry and molecular modelling, the term “force field” is used to describe both
the interatomic potential function and its parameters. For proteins, intensive
development efforts have improved the accuracy of simulations (Durrant and
McCammon, 2011; Klepeis et al., 2009).

3.1.1. Comparison of SSB-Ct Binding Partners
SSB is a protein interaction hub that binds to at least 14 partners in bacterial cells
(Table 1.3). Currently it is known that most SSB-binding partners interact with it
through the SSB-Ct motif, which is highly conserved among bacterial species (Figure
3.1). More recent experimental data from E. coli suggest that the C-terminal tail of SSB
competes with ssDNA for binding to its own OB-domain (Kozlov et al., 2010;
Shishmarev et al., 2014; Su et al., 2014).
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Figure 3.1. Histogram representing the sequence identity of last nine residues of SSB-Ct among 248
bacterial species. Modified from (Lu and Keck, 2008).

Currently, there are four crystal structures reported of proteins in complex with SSB-Ct
or similar peptides: DnaGC (Tak Lo, 2012), RecO (Ryzhikov et al., 2011), ExoI (Lu
and Keck, 2008) and Pol III χ/ψ subunit (Marceau et al., 2011). Common features can
be observed in these SSB-Ct/partner interactions. Where present in the crystal
structures, the acidic residues (the “DDD” sub-motif) are not observed in electron
density or have high B-factors relative to the residues closest to the C-terminus (the
“IPF” sub-motif), which is relatively linear and binds to a hydrophobic pocket on the
surfaces of binding partners. The SSB-Ct peptide can therefore be categorized as a
SLiM (Short Linear Motif). SLiMs typically contain 3 to 10 amino acid residues who’s
primary function is to bind a partner molecule (Via et al., 2015). The four crystal
structures of complexes with SSB-Ct reveal common features: a hydrophobic pocket
that binds to the IPF sub-motif, and this pocket is surrounded by basic residues (Figure
3.2).
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Figure 3.2. Molecular surface of DnaGC (A), RecO (B), ExoI (C) and Pol III χ/ψ (D) with SSB-Ct shown
in stick form. Structures are shown with all SSB-Ct peptides in approximately the same orientation,
Positive and negative electrostatic potentials are shown in blue and red respectively, Figure created with
Coot (Emsley and Cowtan, 2004).

In the case of DnaGC, the binding pocket accommodating the IPF sub-motif of SSB-Ct
is lined by Leu446, Met451, Ile455, Pro480, Leu484, Thr515 and Leu519 (Figure 3.3).
The C-terminal carboxylic acid of SSB-Ct (Phe177) forms a salt bridge with the
guanidinium and amino groups of Arg452 and Lys447. The Ile175 residue forms
hydrophobic contact with Leu446 and Leu519.
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Figure 3.3. Crystal structure of SSB-Ct in complex with DnaGC/SSB-Ct (Tak Lo, 2012). SSB-Ct peptide
residues are underlined. Generated by VMD (Humphrey et al., 1996).

Asp174 makes a hydrogen bond and salt bridge with the side chains of Thr515 and
Lys518 respectively. Asp173 forms salt bridge with Arg452 and Lys447. Mutation of
Lys447 and Lys518 residues to alanine resulted in a 10-fold decrease in KD, while the
Arg452Ala mutant eliminated the interaction (Tak Lo, 2012; Naue et al., 2013). An
alignment of SSB-Ct peptide in all four structures reveals that the conformation of the
IPF sub-motif is surprisingly similar (Figure 3.4).
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Figure 3.4. Structural alignment of SSB-Ct peptide in complex with DnaGC (red), RecO (magenta), ExoI
(green) and χ (yellow). Image generated by PyMol Molecular Graphics System, Version 1.3 Schrodinger,
LLC.

The RMSD of all non-hydrogen atoms in the IPF sub-motif as observed bound to ExoI,
RecO and χ/ψ are 1.7 Å, 2 Å and 0.5 Å with respect to the IPF sub-motif bound to
DnaGC. In all four complexes considered here, an arginine guanidinium group (Arg452
in DnaGC) forms a salt bridge with the terminal carboxylic acid group of SSB-Phe177.
In contrast to the relatively well-conserved conformation of IPF sub-motif, the
conformations of the acidic residues (the DDD sub-motif), where visible, appear highly
variable. It should be noted that in the crystal structure of the Pol III χ/ψ complex, a
truncated peptide (WDIPF) was used instead of the SSB-Ct peptide.

3.1.2 Aim
Two hypotheses regarding the interaction of SSB-Ct with its binding partners may be
advanced based on the crystal structures: (1) the IPF sub-motif is relatively rigid and
makes well defined interactions with its binding partners, and (2) the DDD sub-motif is
relatively disordered and engages in non-specific electrostatic interactions with basic
residues surrounding the immediate vicinity of the SSB-Ct binding pocket. To further
illuminate these interactions, the dynamics of the interactions between SSB-Ct and its
binding partners were probed by molecular dynamic simulations. This was anticipated
to reveal conserved interaction patterns, the basis for the diversity of conformations
observed for the three acidic residues, and to clarify the role (if any) of crystal contacts
on peptide conformation. Furthermore, in silico examination of the impact of the
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following mutations in SSB-Ct (Asp172Asn, Asp173Asn, Asp174Asn (NNNIPF) and
Ile175Leu (DDDLPF)) bound to DnaGC were examined.

3.2 Results and Discussion
3.2.1 Global Structure Behaviour
The structural fluctuations of each system in terms of RMSD is shown in Figure 3.5
and Appendix A. The RMSDs are generally around 2-3 Å, with no significant changes
observed for any of the systems. In contrast, the SSB-Ct peptide shows greater
fluctuations (Figure 3.5B and Appendix A).
The RMSDs for DnaGC/SSB and complexes of DnaGC with mutated SSB-Ct were
broadly similar (Figure 3.5A). DDDLPF shows greater fluctuations; on average 3.8 Å
RMSD with an increase up to 4 Å after 40 ns, most likely caused by the introduced
I175L mutation. The NNNIPF mutant did not show much deviation from the wild type
system.

Figure 3.5. Backbone RMSD plotted for each individual chain of DnaGC/SSB-Ct system along the 100
ns MD simulations. (A) represents RMSDs for the entire DnaGC/wtSSB-Ct (black), DnaG/DDDLPF
(red), and DnaG/NNNIPF (blue) mutated systems, (B) is RMSD for the SSB-Ct peptides. Black is
DnaGC/wtSSB, red is DDDLPF and blue NNNIPF system respectively.

To monitor the structural stability of the systems, the radius of gyration (Rg an
indicative of compactness of the systems) was calculated for all trajectories. In all cases,
the radius of gyration did not show any significant changes from its initial value. All
systems remained stable during the 100 ns simulation. In addition, the secondary
structures of the complexes did not show any significant changes during the simulations
(data not shown).
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3.2.2 Dynamical Behaviour of SSB-Ct
Detailed examination of all simulations showed structural similarities and similar
patterns of interactions. The available crystal structures of all four complexes are
missing some or all acidic residues of the SSB-Ct peptide, suggesting high mobility.
The residue-by-residue RMSD (rRMSD) for each Cα atom was calculated from
molecular dynamic simulations (Figure 3.6). For each trajectory, the SSB-binding
partners were superimposed in their starting positions prior to calculations.

Figure 3.6. RMSD for SSB-Ct Cα atoms for all four systems over 100 ns.

In general, the SSB-Ct peptides showed fluctuations that increased with distance from
the C-terminus. SSB-Ct residues not in direct contact with the binding partner sample a
greater diversity of conformations. The order parameter (S2) was calculated for the
backbone amide nitrogen atoms of SSB-Ct peptide in all four complexes (Figure 3.7) as
follows:
3

3

1
𝑆 2 = [3 ∑ ∑〈𝜇𝑖 𝜇𝑗 〉2 − 1]
2
𝑖=1 𝑗=1
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where μi and μj are the coordinates of the normalized backbone NH vectors,
decomposed into three spatial dimensions (i, j=1,2,3). Values range from 0 (perfect
disorder) to 1 (perfect order).

Figure 3.7. Order parameter (S2) for the SSB-Ct peptide in all four simulations.

The general trend is in agreement with rRMSD calculations, showing that the IPF submotif has higher order (S2 closer to 1) compare to the rest of the peptide.
The volume of space explored by SSB-Ct was visualized by calculating weighted
atomic density maps for the four systems (Figure 3.8).
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Figure 3.8. The weighted atomic density of SSB-Ct peptides in the four simulated complexes, sampled at
1 ns intervals and averaged over 100 ns. The yellow surface, green wireframe and blue wireframe indicate
density contours of 0.07×10-6 Da Å -3, 0.0017 Da Å -3 and 0.0014 Da Å -3 respectively. Density was
calculated using Gaussian distribution of width equal to the atomic radii.

The weighted atomic density analysis shows that the IPF sub-motif remains buried in
the binding pocket while the proceeding residues explore a large volume of space.
In all simulations, the salt bridge formed between an arginine residue and the carboxyl group of Phe177 in the SSB-Ct motif was maintained. This is congruent with
the observation that mutation of the salt-bridge-forming arginine residue to alanine
abolishes interactions in all systems (Lu and Keck, 2008; Marceau et al., 2011; Naue et
al., 2011; Naue et al., 2013; Tak Lo, 2012). Curiously, no hydrogen bonds are formed
between the amide group linking the proline and phenylalanine in SSB-Ct and any of
the binding partners considered here.
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Clustering analysis was carried out for SSB-Ct peptide in the four wild type system
trajectories, as shown in Figure 3.9.

Figure 3.9. Three most populated clusters SSB-Ct conformations bound to DnaGC (A), χ/ψ (B), ExoI (C)
and RecO (D). The starting orientation of the peptide is in green, where blue, red and grey are the first,
second and third most populated clusters respectively.

Clustering analysis shows that SSB-Ct conformations cluster relatively tightly in the
DnaGC and RecO simulations, and that structurally more distinct clusters occur in the
χ/ψ and ExoI simulations. This could indicate that a dominant binding mode exists for
the DnaGC and RecO. In the case of DnaGC, this tight clustering can be explained by
salt-bridge interactions of Arg452 and Lys447 with the central aspartate residue of the
DDD sub-motif (Asp173). A similar pattern occurs in RecO, where a cluster of arginine
residues (Arg210, Arg225 and Arg229) engage in salt bridge interactions with the
residues in the DDD sub-motif. In the case of χ/ψ and ExoI, the peptide clusters
represent relatively low-population conformations where acidic residues form salt
bridges with residues on the surface of those proteins. The patterns are detailed in Table
3.1.
The backbone dihedral angles of SSB-Ct peptide (DnaGC/wtSSB) were monitored
during the simulation. Residue Pro176 likely plays the role of a “conformational lock”
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orienting the residues on either sides of it. The cyclic pyrrolidine group of Pro176 fixes
the backbone dihedral Φ angle (C-N-Cα-C) in the range preferred for α helices (~60°),
but leaves dihedral angle the ψ (N-Cα-C-N) relatively unrestrained. In the DnaGC
complex, Φ = -85° and ψ = 37°.
It was observed that Phe177 in DnaGC/wtSSB-Ct complex showed significant
structural differences compared to the in silico Ile175Leu mutant. In the
DnaGC/DDDLPF simulation, Phe177 moves away from the pocket, and at 60 ns it
reaches a critical point where its phenyl ring is no longer in the pocket, which explains
the increase in RMSD after 60 ns (Figure 3.5). In silico mutations of SSB-Ct peptide
(Asp172Asn, Asp173Asn and Asp174Asn) had a significant impact on orientation of
peptide bound to DnaGC; the loss of electrostatic interactions appeared to allow
movement of Phe177 out of the pocket. The salt bridge between the Phe177 α-carboxyl
group and Arg452 breaks at about 84 ns mark, which makes peptide more flexible and
completely changes its orientation. Therefore, while the DDD sub-motif does not
participate in long-lived interactions on the surface of SSB-Ct, it does appear to help
stabilize the binding of the IPF sub-motif.
In general, interactions observed in available crystal structures were maintained in the
MD simulations (Table 3.1). The SSBCt-Phe177 was observed to engage in salt bridge
interactions with arginine with a population > 50% (Table 3.1). Consistent with the lack
of hydrogen bonds in the crystal structures, the amide group linking SSB-Ct residues
Pro176 and Ile175 form hydrogen bond with low occupancies (Table 3.1).
The DDDLPF mutant has reduced populations of some of the hydrogen bonds. In the
case of the RecO/DDDLPF system, the Phe177:Arg132 interaction showed decreased
hydrogen bond population (45%) compared to wild type (69%). Nevertheless in
DnaGC/DDDLPF Pro176 gets closer to Lys447 to form short-lived hydrogen bond.
Of the four aspartate residues in SSB-Ct, Asp173 engages in the most direct hydrogen
bonding or salt-bridge interactions (Table 3.1). Asp to Asn mutations in SSB-Ct
dramatically decreased the population of direct interactions, suggesting that the
presence of formal charges are important for the SSB-Ct/binding partners interactions.
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Table 3.1. Occupancies of hydrogen bonds between SSB-Ct residues and all four wild type systems. Interactions with less populations of > 5% were excluded.

DDDLPF
NNNIPF

F171

D/N172

D/N173

-

-

-

-

-

-

Gln445

-

-

-

-

-

-

-

-

-

-

-

-

-

Lys518

8%

-

-

Arg327

-

78%

-

-

-

-

-

-

Lys206

14.3%

Arg452

79%

Lys447

-

-

-

-

-

-

-

-

-

Arg448

-

-

-

-

-

-

-

-

-

Arg448

19%

Lys518

11%

-

-

-

-

Thr449

10%

Arg452

~100%

Arg452

60%

Lys447

10%

-

Gln445

15%

Pro444

6%

-

-

2%

Arg207

68%

Arg229

10%

Arg229

15%

Arg210

53%

-

-

-

-

Arg229

15%

χ

-

-

Arg203

Arg210

Arg203

-

-

-

-

F177

-

Arg203

-

P176

-

45%

-

I/L175

-

Arg225

-

D/N174
-

-

10-20%

RecO-DDDLPF

RecO

ExoI

DnaGC-

DnaGC-

DnaGC

D170

-

Arg135

13%

Arg135

32%

11%

-

-

-

-

Arg452

69%

-

-

-

-

Arg148

32%

Arg203

83%

Arg132

69%

Lys206

15%

Arg225

40%

Arg132

45%

Arg210

46%

Arg225

31%

Lys206

6%

Arg148

69%

-

-

-

-

-

Lys206

-

11.2%

62%

65%

-

-

-

-
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3.2.3 Electrostatic Interactions
The importance of acidic residues in SSB-Ct, and the presence of basic residues around
the SSB-Ct binding site was noted above. To understand the relationship between the
architecture of the complexes and electrostatic forces at play, the electrostatic potential
has been mapped (Figure 3.10). The contrast between the wild type SSB-Ct and
NNNIPF mutant can be clearly seen in the difference between their electrostatic
potentials: the region of negative potential due to the SSB-Ct peptide is juxtaposed with
the positive potential around the SSB-Ct binding pocket. In NNNIPF-Ct peptide, only
intact Asp170 was involved in charged interactions with Lys447 and Lys518 (Table
3.2). These data support the hypothesis that non-specific, long-range electrostatic
interactions contribute to SSB-Ct/binding partner interactions.

Tab 3.2. The list of residues of DnaGC involved in salt bridge formation with wild type, DDDLPF and
NNNIPF mutated complexes over the trajectories.

SSB-Ct
residues
Asp170

wtSSB-Ct
complex
Lys447, Lys518

DDDLPF
complex
Lys447, Arg448,

NNNIPF
complex
Lys447, Lys518

Lys518
Asp/Asn172

Lys447, Arg452,

Arg448

-

Lys447, Arg448,

-

Lys518
Asp/Asn173

Lys447, Arg452

Arg452
Asp/Asn174

Lys518

Arg448, Arg452,
Lys518
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Figure 3.10. Electrostatic potential map orthogonal to the Y axis for wild type DnaG/SSB-Ct (A) and
NNNIPF (B) systems. Protein represented in yellow and orange ribbon, the peptide is in stick
representation (B). Values are in kT/e.

3.4 Conclusion
A simulation-based approach was used to study the behaviour of SSB-Ct/binding
partner interactions. The integrity of the simulated systems was demonstrated by the
maintenance of interactions observed in the crystal structures being maintained
throughout the simulations. Low-population interactions between SSB-Ct and binding
partners were detected that were not observed in the crystal structures (e.g. hydrogen
bonding in RecO/SSB-Ct between Arg207 and Aps173; Arg210 and Asp173). These
interactions could be further probed by site-directed mutagenesis and binding assays.
The importance of acidic residues in the SSB-Ct peptide was conformed by in silico
mutagenesis: the loss of charged aspartate residues in the DDD sub-motif destabilized
peptide binding. Those data, and the data from the other SSB-Ct complexes suggest that
non-specific electrostatic interactions play an important role in SSB-Ct binding. The
substitution of Ile175 to leucine was shown to affect the orientation of the Phe177 in the
binding pocket, most likely due to steric reasons, which explains the reduction of the
measured binding affinities (unpublished data).
Overall, the MD results are in agreement with currently available mutagenesis data
supporting that presence of acidic residues in the SSB-Ct are essential for this
interaction. Similarities in amino acid composition of binding pockets were determined.
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4.1.1 Introduction
Screening a fragment library containing hundreds of compounds requires highthroughput capability coupled with the sensitive detection of fragment binding. SPR and
ligand-based NMR methods are able to measure weak protein-fragment interactions and
are the most popular primary screening tools (B J Davis and Erlanson, 2013). SPR is a
powerful label-free biophysical technique for the detection of protein-protein and
protein-small molecule interactions in real time (Neumann et al., 2007). To detect
binding, receptor molecules are immobilized on the sensor surface, and a solution of
analyte (e.g. a fragment) is continuously injected onto the flow cell. The detection of
binding is based on SPR phenomenon. Changes in micro-environment on the chip
surface affects the reflection of the polarised light angle upon interaction, which is
recorded by a detector. The method can be used for competition experiments, where the
receptor is immobilized on the surface and the known binding partner is injected with
the fragments to be tested. Competition assays provides additional information about
the fragment binding location. In addition to measuring binding affinities, SPR can be
used to measure binding kinetics (Cooper, 2002) (See section 1.2.2.3).
NMR provides robust methods for testing the binding of fragments and measuring the
binding affinities. Since NMR was first used as a screening tool (Hajduk, 2006), the
available methods have evolved. From a screening prospective, NMR-based methods
can be divided into two groups: protein- and ligand-based (Dalvit and Stockman, 2002).
STD-NMR is the most commonly used ligand-based NMR method. It is composed of
on- and off-resonance experiments. In the on-resonance step, selective irradiation of
protein protons ensures that saturation is efficiently propagated across the entire protein.
In case of ligand binding, magnetization is transferred from protein to bound ligand via
spin diffusion (Mayer and Meyer, 1999). Care must be taken to choose the range of
spectrum for irradiation so as to avoid compound resonances that could result in false
positive hits. For that purpose, the -1 to 1 ppm range is used, which is usually free of
ligand signals, and is dominated by protein methyl groups. In the event of ligand
binding and where protein-ligand 1H-1H distances are short (< 6 Å), magnetization
transfers from protein to the transiently bound ligand via the intermolecular NOE. Small
molecules bound to proteins reflect the properties of the larger molecule, i.e. they
exhibit negative NOEs. Compound peaks are therefore decreased in on-resonance
spectra. In the off-resonance experiment, selective pulses are applied to the spectral
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region devoid of either protein and ligand signals, e.g. -40 ppm. This generates a
reference spectrum, whereby the signals of neither protein nor ligand are saturated. By
subtracting the on-resonance (saturated) from off-resonance (non-saturated) spectra, the
final STD spectrum is generated. It contain peaks for compounds that bind to the protein
(Mayer and Meyer, 1999; Angulo and Nieto, 2011; Viegas et al., 2011). The STD
experiment is illustrated in Figure 4.1.

Figure 4.1. Illustration of the STD-NMR experiment. At the top are NMR spectra before and after
selective saturation of protein, with final STD spectrum generated (right top), the peaks in green due to a
compound that binds to protein from the cocktail, while the peaks in blue correspond to a non-binding
compound. At bottom-left is the fragment cocktail with protein. The blue arrows indicate selective
irradiation to saturate the protein and its transfer to bound ligand.

Recently, fragment screening for inhibitors of protein-protein interactions (PPI) using
ligand-based NMR methods was demonstrated. It was shown that varying the protein
concentration (maintaining the ligand concentration fixed at 1 mM), may lead to
improved ability to detect weak binders (Dias et al., 2014). To enhance the signal to
noise ratio (S/N) or saturation efficiency, protein stability and compound solubility,
experiments are often carried out at around 10 °C in 100% 2H2O buffer (Begley et al.,
2013; Mayer and James, 2002). The STD method is frequently used to screen fragment
cocktails. One limitation of fragment screening is the solubility of individual fragments
as well as cocktails of fragments in aqueous conditions used for screening. Therefore,
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prior to any measurements, the solubility and aggregation properties of ligands in
cocktails should be assessed so as to avoid promiscuous binders. Peaks in the 1D 1HNMR spectra of cocktails should not overlap (LaPlante, Carson, et al., 2013; LaPlante,
Aubry, et al., 2013; Doak et al., 2013).
Because of its high-throughput nature, STD-NMR is useful in the early stages of
screening. It can be used for deducing the binding affinities and ligand epitope mapping.
By monitoring the intensity changes during the experiment, the functional groups in
ligands that are in closer proximity to the target protein can be identified (Mayer and
Meyer, 2001). Additionally, the principals of STD can be easily transferred to 2D-NMR
experiments, such as 2D STD-COSY (Wagstaff et al., 2010). Affinity measurements of
weakly binding compounds using STD titration are not accurate due to errors in
saturation time, protein concentration and intensity of the monitored signals (Angulo et
al., 2010).
In spite of the aforementioned advantages, STD-NMR has a high false positive rate due
to the inability to differentiate between specific and non specific-binding, and the
aggregation of fragments (Vom et al., 2013; Doak et al., 2013). Therefore, cross
validation of hits from STD-NMR screens with other ligand-based methods is
recommended (Dias et al., 2014).

4.1.2 Aim
The overall aim was to identify first generation of fragment hits targeting the SSB-Ct
binding pocket and catalytic domain of DnaG primase. Initially, an attempt to use X-ray
crystallography as the screening method was undertaken, however, suitable crystals
were not forthcoming. A SPR competition assay and ligand-based STD NMR were used
instead (initially against the RCD). SPR hits were also cross-validated by STD NMR.

4.2 Results and Discussion
4.2.1 Crystallography
Initially, an attempt was made to use protein crystallography as a primary fragment
screening method. Purified DnaGC was subjected to crystallization experiments as
reported previously (Oakley et al., 2005; Loscha et al., 2004), resulting only in protein
precipitation. Therefore, screening for new conditions using the JCSG+ screen
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(Newman et al., 2005) was attempted in order to find new conditions and no crystals
were observed after several weeks.
Crystallisation trials were then carried out on RCD, varying the protein concentration,
temperature (4 °C and 22 °C), using JCSG+, PEG, PEG II and PACT crystallisation
suits (Newman et al., 2005; Krosky et al., 2006). Protein precipitated in about half of
the conditions, confirming that protein concentration was not low. No crystals were
observed even after several months. These could be influenced by presence of flexible
linker between two domains of RCD protein, as well as by many other factors affecting
crystallisation process (protein batch, temperature, concentration, pH etc.).
Alternative screening approaches, utilising SPR and NMR methods were undertaken.

4.2.2 Primary screening using SPR competition assay
A SPR competition assay was used to test the “first pass screen”, a fragment screen by
Zenobia Therapeutics. The RCD component of DnaG was used for fragment screening.
The primary target of interest was SSB-Ct and DnaG interaction, which has been shown
to occur via C-terminal domain of DnaG primase (Tak Lo, 2012; Naue et al., 2013).
The presence of two domains in the RCD could increase the hit rate, as the presence of
two domains provides additional surface area for fragment binding. However, this
would require effects from fragment binding to the RNAP domain to be transmitted by
some allosteric mechanism to the C-terminal domain. The SPR competition assay with
immobilised SSB-Ct peptide on the chip surface (Figure 4.2A) and RCD pre-incubated
with fragments as the analyte was conducted. An experimental setup using the
biotinylated SSB-Ct peptide immobilized on the chip surface and using RCD as an
analyte resulted in a relatively large mass change on the chip surface and hence a strong
SPR signal. The solubility of fragments under experimental conditions was tested at
concentrations of 1 mM. Solutions containing fragments were flowed across the chip
surface prior to peptide immobilization to eliminate those that bound non-specifically to
the gold surface of the chip and which would give a false positive response. It was
observed that the level of response showed a gradual decrease compared to initial levels,
most likely due to loss of peptide from the surface.
Subsequent injections of RCD and RCD-fragment mixtures, generated sensorgrams
such as the one shown in Figure 4.2B. As expected binding affinity is weak (with KDs
in the millimolar range), small changes (in the order of 5-10 RU) are considered
positive hits (Figure 4.2B).
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Figure 4.2. SPR experimental setup. (A) Biotinylalted SSB-Ct peptide immobilized on streptavidine chip
surface. (B) competition sensorgram for the compound D6. The black trace corresponds to RCD and blue
with RCD + D6.

The “first pass screen” using the SPR competition assay identified 6 compounds that
compete with SSB-Ct for the RCD. The structure of all of the six fragments are shown
in Figure 4.3.

Figure 4.3. The chemical structures of SPR hits.
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4.2.3 Validation of SPR hits and identification a new hits by STD-NMR
The 6 fragments from the “first pass screen” were retested by STD-NMR. Each
fragment was tested separately at 1 mM concentration. STD gave rise to smaller peaks
in the NMR spectra for all of 6 compounds confirming the binding to the RCD protein
(Figure 4.4).

Figure 4.4. STD spectrum of SPR hit D6 confirmed by STD-NMR. Red represents 1D 1H of ligand alone
and blue is final STD spectrum

Concurrent with the confirmation of SPR hits by STD-NMR, the MIPS library was
screened. The MIPS library was designed specifically for NMR screening and contains
about 1200 fragment with diverse structures (Doak et al., 2013). Each cocktail
contained 6 fragments, with diverse functional groups chosen so as to minimize overlap
in 1D 1H NMR spectra. Spectral interference from buffer was minimized by use of
2

H2O. The use of 2H2O confers an additional advantage whereby leakage of saturation is

minimized (Mayer and James, 2002; Begley et al., 2013). In order to enhance the S/N,
experiments were performed at 10 °C. Lowering the temperature improves the affinities
of ligands that binds exothermically (Howard et al., 2013), enhances the protein
stability and compound solubility. Fragment cocktails that precipitated in the screening
buffer were excluded. A typical STD spectrum from screening fragment cocktails is
shown in Figure 4.5.
64

Chapter 4: Fragment-Based Screening Against C-terminal Domain of DnaG primase

Figure 4.5. STD-NMR spectra of one of the rank 3 compounds. Spectra labelled 1-6 represent 1D 1H
NMR spectra of each individual compound present in the cocktail. In blue is the STD spectrum in the
presence of protein. Arrows highlighting peaks indicating the peaks appearance in STD spectrum
confirming that second compound binds to protein from a cocktail.

Assessment of STD experiments was based only on the aromatic region of the
spectrum. In order to analyse the STD experiments and differentiate the quality of
binding, a ranking system based on comparison of the STD signal intensity was applied:
rank 0-no STD; 1-possible hit, very week intensity; 2-clear hit, moderate intensity and
3-clear hit, strong intensity) (Doak et al., 2013). Fragments with a positive STD signal
from the cocktail screen were re-tested as pure ligands using the same technique. The
overall STD hit rate was 17%: 56 compounds were rank 3 (clear hit, strong intensity),
62 were rank 2 (clear hit, moderate intensity), and 82 were rank 1 (possible hit, weak
intensity). The chemical structures of identified fragments are listed in Appendix B. Of
the rank 3 compounds, 26 (about half) were identified as “frequent hits” (Doak et al.,
2013) and were excluded from further consideration. Similarly, 24 of the rank 2 hits
were excluded.
The STD-NMR experiments were done primarily to identify fragments binding to SSBCt binding pocket of DnaG primase. As the protein used contained the RNA polymerase
domain further experiments are required to distinguish those compounds that bind to the
RPD domain.
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4.2.4 Chemistry of hits
Those hits (from both libraries) showing interaction with RCD by two different
biophysical methods display some structural similarities (Figure 4.6). Apart from
having hydrophobic moieties such as phenyl rings and heterocyclic groups (commonly
indole, diazole, benzodiazole and oxygen containing heterocycles etc.), some of them
also include sulphonamide and carboxylic acidic motifs that could be mimicking the
carboxylic acid moiety of Phe177 in SSB-Ct. Residues engaged in salt bridge
interactions with the carboxy-terminus of SSB-Ct are conserved across binding partners,
as shown in crystal structures and MD simulations described in Chapter 3.

Figure 4.6. Comparison of some of the SPR and STD hits.

4.3 Conclusion
Initially an attempt to use crystallography for fragment screening against DnaGC was
made. As no suitable crystals of DnaGC or RCD proteins were forthcoming, SPR and
STD-NMR approaches were used. The Zenobia “first pass screen”, containing 350
fragments, was screened in a SPR competition assay. Hits from the SPR experiments,
and the MIPS fragment library were rescreened by STD-NMR. Fragment hits against
the SSB-Ct binding pocket and RNA polymerase domain were identified.
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5.1 Introduction
The next step in this project was to identify the binding pocket(s) of identified
fragments on the surface of the target protein. Protein-based NMR methods can give
information about ligand binding and dynamics of the complex and in some cases can
give rise to NOEs which are transferred to distance restraints (Petros et al., 2014).
Several methods have been developed for studying proteins and protein/protein
interactions by NMR, the most common being

15

N/13C-HSQC. The availability of

cryogenic probes and improved pulse sequences make it possible to obtain protein
resonances at lower concentrations of protein (e.g. at 50 μM using SOFAST-HSQC)
(Schanda et al., 2005). High acquisition speeds allow for high-throughput experiments.
Using TROSY-based experiments with various isotopically selectively labelled samples
allows the method to be applied to larger proteins (> 100 kDa) (Riek et al., 2000). With
15

N-labelled biomolecules, it provides a high-resolution ‘fingerprint’ of the protein.

Each amino acid except proline is represented by a single backbone amide peak. An
extra peak is observed for the indole-containing side chain of tryptophan and two extra
peaks are observed for the side chains of asparagine, glutamine. In certain cases an
additional peak is observed for side chains lysine and arginine (Kwan et al., 2011). A
2D-HSQC spectrum of 15N-enriched protein with ligand allows ligand-binding locations
to be determined. Where binding occurs, changes in chemical shifts are observed.
Chemical shift perturbation (CSP) mapping provides crude structural information.
Chemical shifts are precise, reproducible and are very sensitive to their local
environments. Therefore, small changes in structure and/or dynamics are readily
detectable (Williamson, 2013; Pellecchia et al., 2002). An important caveat is that CSPs
may be due to allosteric effects. Thus, CSP may not exclusively show the exact binding
site. In such cases, comparison of spectra of two similar ligands is recommended
(Pellecchia, 2005).
In cases where crystal structures of bound fragments are not available, molecular
docking may provide insights into how the ligand is oriented in the pocket. The main
disadvantage of “unrestrained” docking calculations is that discriminating between
native and non-native orientations is difficult (Wang et al., 2007). The presence of
restraints (e.g. CSP, NOE-restrains) significantly improves the accuracy of molecular
docking. CSPs can be used to generate docking restraints. However, CPS data is most
commonly used as a final filter of poses generated by docking (Stark and Robert
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Powers, 2008) Medek and co-workers have shown that similar ligands with similar
binding poses generate similar CSPs (Medek et al., 2000).
19

F-NMR can also provide valuable data for the study of protein-ligand interactions.

The high sensitivity and specificity of the method makes it a valuable tool for structural
biology and drug design (Chen et al., 2013).

19

F has ½ spin without a quardrupole

moment, thereby significantly simplifying the interpretation of spectra. It’s short
longitudinal relaxation rate (R1) makes spectral acquisition relatively fast. It has a
natural abundance of 100% and a high gyromagnetic ratio, resulting in strong dipolar
coupling (e.g.

19

F-19F and 1H-19F NOEs) that can be used as distance restraints in

structural calculations. Fluorine-19 displays a wide range of chemical shifts (-300 to
400 ppm). It allows precise detection of changes in chemical environments. Its NMR
signal is free of background signals from proteins and/or buffers. The acquisition of 19F
spectra does not require the use of deuterated buffers and is therefore cost-effective.
While fluorine has a larger van der Waals radius compared to hydrogen (1.35 Å vs 1.10
Å), studies have shown that the additional steric demand of fluorine in comparison to
hydrogen is small (Duschinsky et al., 1957). Incorporation of fluorinated amino acids
into proteins (in aliphatic or aromatic side chains) does not usually cause structural and
functional changes (Didenko et al., 2013; Vulpetti et al., 2009; Dalvit et al., 2004). The
replacement of hydrogen with fluorine in drugs has many advantages. Typically, its
influence on the metabolic profile of compounds is to block oxidation (Hagmann, 2008;
Purser et al., 2008). These properties of 19F nuclei render it a useful screening tool. It is
noteworthy that the S/N ratio of 1D

19

F spectra can be improved by use of cryogenic

probes and by increase of the field strength of the spectrometer.

5.1.2 Aims
The aim is to validate the first generation hits using protein-based NMR techniques, to
identify binding sites on DnaGC, the elucidation of fragment binding-modes and
biophysical characterisation of binding. Furthermore, hit-to-lead optimisation using in
silico approaches were performed.
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5.2 Results and Discussion
5.2.1 15N-HSQC Buffer Optimisation of DnaGC
The structure of DnaGC was determined by crystallography and NMR (Oakley et al.,
2005; Su et al., 2006). There are two NMR experimental conditions described for
DnaGC (1) 10 mM phosphate buffer (pH 6.0), 100 mM NaCl, 1 mM DTT and 0.1%
(w/v) sodium azide (Su et al., 2006), and (2) 5 mM potassium phosphate (pH 7.4), 5
mM NaCl, 2 mM DTT (Naue et al., 2013). The latter condition was used to identify the
SSB-Ct binding pocket, although certain residues, Lys447, Arg448, Thr449, Asn511,
near the SSB-Ct binding site, and Asn565 in the hairpin turn near the C-terminus were
not detected in

15

N-HSQC spectrum of the apo-protein. Resonances due to those

residues appeared in the spectrum only in the presence of an excess of SSB-Ct peptide
(Naue et al., 2013). Therefore, condition 1 was chosen. To avoid possible pH changes
caused by addition of some of the ionisable ligands, condition 1 was slightly modified
by replacing the phosphate by 50 mM MES, which is recommended for pH range
between 5.5 to 6.5 (Kelly et al., 2002). The 2D

15

N-HSQC spectrum of DnaGC in the

optimised buffer is shown in Figure 5.2.

Figure 5.2. 15N-HSQC spectrum of DnaGC. Spectrum was recorded at 298 K using 100 μM protein.
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All backbone amide peaks in 15N-HSQC were assigned and in most cases showed some
small shifts relative to the spectrum reported by Su and co-workers (Su et al., 2006).

5.2.2 15N-HSQC Assignment Propagation of DnaGC and First
Generation of Hits
The influence of organic solvents in shifting peaks in NMR spectra is well known
(Liepinsh and Otting, 1997). In order to minimise the possibility of false positive
results, and to exclude the effects of DMSO on CSPs, DMSO was mixed with

15

N-

DnaGC and a HSQC spectrum was acquired. DMSO concentrations of up to 2% (v/v)
did not shift any peaks. Rank 2 and 3 compounds (68 fragments; see Chapter 4) that
were not classified as “frequent hits” were assessed for binding using

15

N-HQSC.

Spectra were recorded for the apo-protein (100 μM) and after addition compounds (3.3
mM). Where binding occurs, peak shifts and/or intensity changes are expected (Figure
5.3, Appendix C). Weak protein-fragment interactions often have high dissociation rate
constants (koff), resulting in averaged chemical shifts from both ligand-free and ligandbound states (i.e. separation of NMR signals for free and bound forms does not occur),
which is typical for fast-exchange systems (Dalvit and Stockman, 2002).

Figure 5.3. 15N-HSQC spectrum of apo
fragment (green).

15

N-DnaGC (black) and upon addition of 3.3 mM L1H10

71

Chapter 5: Structural and Biophysical Characterisation of Hits

Therefore, chemical shift changes were assigned using the nearest-neighbour approach.
By mapping the CSP data to the protein surface, the binding locations of the fragments
were identified. The STD hits that were confirmed by 15N-HSQC NMR measurements
were ranked according to CSP magnitude (section 2.2.4.5) in order to identify the most
potent fragment. Typically, perturbations were considered significant if Δδ > 0.02 ppm
for at least two peaks in the spectrum using Eq. 2.2 (Hajduk et al., 2000). 12 fragments
were assigned as rank 3 and 2 by HSQC (Table 5.2), and 56 fragments gave no
perturbations.
Table 5.2. The list of HSQC hits. Compounds were ranked according to CSP magnitude. The number of
rotatable bonds and cLogP was estimated using Instant JChem 6.1.5, 2014, ChemAxon
(http://www.chemaxon.com).

Name

Structure

L3F10

HSQC

Number of rotatable

rank

bonds

3

1

1.44

3

1

0.98

3

1

1.35

3

1

1.63

3

1

1.4

3

3

1.87

3

4

2.4

Cl
N

N
H2N

cLogP

O

L3H1

N
NH
O

NH 2
HN

L4B4

OH
O

NH

C2G4

OH

N
NH 2
NH

H2N

N

C4C4

–

F

L1H10

N
N

N

NH

S

OH
O

L1A11

S

OH

O
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Name

L1G8

Structure

HSQC

Number of rotatable

rank

bonds

3

2

1.42

3

2

1.72

2

0

1.93

2

1

2.30

2

2

2.45

O
O

cLogP

N
OH

L6D1
Cl

NH
O

S

L1F5

O

N
CH3
S

HO

L1C6

O
N

C9C12

CH3

HN
NH 2
H3C

O

HO

Comparing the CSP data for fragments confirmed by

15

N-HSQC NMR shows similar

patterns of chemical shifts (albeit with different magnitudes), confirming that all
fragments bind to the same pocket. Residues Arg452 Arg452 (15N-118.54 ppm, 1H-7.53
ppm), Lys518 (15N-119.2 ppm, 1H-7.8 ppm), Thr449 (15N-114.79 ppm, 1H-7.59 ppm)
and Gly481 (15N-113.9 ppm, 1H-8.6 ppm) were most susceptible to perturbation upon
addition of fragments (Figure 5.4, Appendix C). Number of rotatable bonds does not
include bonds with hydrogen atoms.
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Figure 5.4. SSB-Ct binding pocket of DnaGC. Representation of residues most susceptible to CSP upon
addition of fragments.

These residues are also vital for binding SSB-Ct peptide. Four fragments (L1G8 (2-[2oxobenzo[cd]indole-1(2H)-yl]acetic acid), C4C4 (5-(4-fluorophenyl)-1H-1, 2, 3, 4tetrazole),

L1H10

((1H-indole-3-ylsulfanyl)acetic

acid)

and

L1A11

(3-

(phenylsulfanyl)propanic acid)) (Figure 5.5) have been chosen as the starting point for
further optimisation, based on strong CSP changes (Appendix C). In spite the fact that
HSQC experiments identify the binding site, they do not provide the binding orientation
of fragments. The binding site location can nevertheless be used for CSP-guided
molecular docking to predict the binding orientation of fragments.

Figure 5.5. The four best fragments estimated binding affinities identified from primary screening.
Binding affinities were estimated by 15N-HSQC titration.
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5.2.3 Biophysical Characterisation of Confirmed Hits
Binding affinities of fragments were estimated by HSQC titration experiments, without
exceeding the 2% (v/v) DMSO level used previously. Peak movement were monitored
throughout the titration and, chemical shift changes were measured for each single
concentration point (Figure 5.6).

Figure 5.6. Binding affinities measured by HSQC titration of (A) C4C4, (B) L1G8, (C) L1H10 and (D)
L1A11. Different curves corresponds to different perturbed residues upon addition of fragment.

All four fragments (C4C4, L1H10, L1A11) showed similar affinities to DnaGC. The
highest affinity was shown for the L1G8 fragment, possibly as a result of occupying the
shallow binding pocket with its hydrophobic skeleton (discussed in 5.2.4). It is often
difficult to measure the binding affinity of weak binding ligands caused by protein
and/or ligand solubility and as a consequence KD is underestimated (Fielding, 2007).

5.2.4 CSP-Guided Molecular Docking
In the absence of experimental data, computational approaches can be used to predict
the structures of protein/ligand complexes. Using molecular docking calculations, it is
possible to predict the orientations of small molecules in binding pockets. Docking
algorithms generate possible orientations of ligands, which when complimented with
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experimental results from protein-based NMR methods, may assist in the identification
of the most likely ligand orientations within a binding pocket.
The crystal structure of the DnaGC/SSB-Ct complex was used to dock the fragments.
For this purpose, Autodock Vina 1.1.2 was used (Trott and Olson, 2010). It is
computationally efficient and gives relatively low standard errors of free energy of
binding (compared with theoretical and experimental free energy of binding) of 2.85
kcal/mol (Trott and Olson, 2010). It uses combined knowledge-based potentials and
empirical scoring functions. It has also shown higher success rates and computational
efficiency compared to other docking programs (Krüger et al., 2012).
The crystal structure of DnaGC/SSB-Ct complex revealed that there is no major
conformational changes upon binding of SSB-Ct peptide to DnaGC (Tak Lo, 2012),
therefore in all docking calculations, the protein remained static and flexibility was
afforded to ligand molecules. The docking grid covered the SSB-Ct binding pocket,
with dimensions 16 Å x 16 Å x 14 Å, centred on the binding location of SSB-Ct residue
Phe177. The 4 fragments selected based on the HSQC experiments above were docked,
and the first three low energy conformers are shown in Figure 5.7. Only first pose of
the docked fragments was considered for detailed description of interactions with the
binding pocket of DnaGC (Dr. Haibo Yu personal communication). The binding free
energy is shown in Table 5.3.

Table 5.3. The binding free energy of docked poses of first generation of fragments generated by
Autodock Vina. Binding free energies are in kcal/mol.

Pose 8

Pose 9

Pose 10

Pose 7

-5.1

-5.1

-5.1

-5.0

-4.9

-4.9

-4.7

-4.7

-4.7

-4.7

L1G8

-5.7

-5.5

-5.5

-5.4

-5.3

-5.3

-5.2

-5.2

-5.2

-5.2

L1H10 -5.4

-5.1

-5.0

-5.0

-4.9

-4.9

-4.8

-4.8

-4.6

-4.6

L1A11 -4.7

-4.7

-4.6

-4.6

-4.6

-4.5

-4.5

-4.5

-4.5

-4.5
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Pose 6

Pose 5

Pose 4

Pose 3

Pose 2

Pose 1

C4C4

Figure 5.7. Predicted orientations of the best four first generation of hits (L1G8 (A), C4C4 (B), L1A11 (C) and L1H10 (D)). The 3 lowest energy poses shown. Figure
was generated using VMD (Humphrey et al., 1996).
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The MD simulations described in Chapter 3 and the crystal structure of DnaGC/SSB-Ct
complex indicate that Arg452 is extensively involved in hydrogen bonding/electrostatic
interactions with carboxylic acid group of Phe177. CSP-guided molecular docking
suggests that all 4 compounds interact with Arg452 (15N-118.54 ppm, 1H-7.53 ppm).
Detailed examination of a predicted orientation of L1G8 fragment is shown in Figure
5.8. The shallow hydrophobic pocket is occupied by the tricyclic skeleton (Figure
5.8A).

Figure 5.8. NMR-guided docking of L1G8 fragment. (A) Lowest energy docked binding pose of L1G8.
Schematic representation of binding pocket with charged interactions between protein and fragment (B).

While the carbocyclic skeleton forms hydrophobic contacts with the pocket, the
carboxylic group forms a salt bridge with the positively charged side chain of Lys518
(15N-119.2 ppm, 1H-7.8 ppm). The carbonyl oxygen of this fragment forms a hydrogen
bond with Arg452. Interestingly, one of the other fragment hits, L1C6, has the same
chemical skeleton as L1G8, but with the carboxylic acid group replaced by a methyl
group. Spectral overlay of two compounds in complex with DnaGC, 15N-HSQC spectra
indicates that fewer peaks have shifted compared with L1G8, in agreement with
molecular docking. Additionally CSP-magnitudes are smaller compare to L1G8 (Figure
5.9, Appendix C). The data suggests that charged interactions of the L1G8 carboxylic
acid motif contribute significantly to the interaction with DnaGC.
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Figure 5.9. Comparison of CSP induced by L1C6 (red) and L1G8 (blue) compounds with chemical
structures of two fragments. The apo-protein spectrum is in black.

CSP-guided molecular docking of C4C4 compound with DnaGC is shown in Figure
5.10.

Figure 5.10. C4C4 docked into DnaGC. The lowest energy docked pose of the fragment in the DnaGC
pocket is shown (A), and schematic representation of residues interacting with fragment (B).

In spite that fact that L1G8 has better binding affinity, C4C4 is predicted to make more
contacts with the binding pocket that are potentially exploitable in lead optimisation
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(Appendix C). Compound C4C4 contains a tetrazole group, a bioisosteric alternative to
the carboxylic acid group (Malik et al., 2013). It has a low pKa (~5) and is good
hydrogen bond acceptor. Modelling studies suggest that replacement of carboxylic acids
with tetrazole increases the hydrogen bond strength (Allen et al., 2012). The tetrazole
ion forms electrostatic and hydrogen bond interactions with the side chains of Lys447,
Thr449 and Arg452. The phenyl ring appears likely to mimic the last phenylalanine
residue (Phe177) in the SSB-Ct peptide and makes hydrophobic interactions with
residues Pro480, Gly481, Thr515 and Leu519. The presence of a fluorine atom is
expected to increase the acidity of the tetrazole due to its electron-withdrawing nature
(Dalvit et al., 2014). The fluorine atom is in contact with the amide group of Gly481
and the methyl groups of Leu448, Leu455, Thr515, Leu516 and Leu519 (Figure 5.10).
These residues are forming the edge of the peptide binding pocket.
Fragment L1A11 has a slightly different binding pose compared to other three
fragments. The carboxylic motif is directed towards the edge of the pocket and forms
hydrogen bond interactions with amide group of Gly481. In the docked model of
L1A11, the sulfur atom simultaneously interacts with the guanidine group (3.6 Å) and a
backbone amide proton (3.2 Å) of Arg452 (Figure 5.11).

Figure 5.11. Visualization of binding of L1A11 fragment. Lowest energy orientation of fragment, in the
DnaGC pocket (A). Schematic representation of residues interacting with fragment (B).
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In case of the L1H10 fragment the aromatic ring is surrounded by Leu446, Thr515 and
Leu519 forming various hydrophobic σ-π contacts. The indole ring is buried in the
hydrophobic pocket formed by methyl groups of Ile455, Gly481, Leu484 and Leu519.
Meanwhile Gly481 interacts with the nitrogen atom of indole (Figure 5.12). The
carboxylic group interacts with Lys447 and Arg452.

Figure 5.12. Visualization of binding of L1H10 fragment. Lowest energy dockedorientation of fragment
in the DnaGC pocket (A). Schematic representation of residues interacting with fragment (B).

Fragments LA11 and L1H10 both contain carboxylic acid and thioether groups.
Thioethers have a hydrophobic character, but sulphur is also a very weak hydrogen
bond acceptor. The importance of anionic motifs was been demonstrated in the cases of
L1G8 and C4C4 fragments. A negative charge on the ligand therefore appears necessary
for targeting the SSB-Ct/DnaGC interactions.

5.2.5 In Silico Hit to Lead Optimisation
2D NMR confirmed that most of the fragment hits were binding to the SSB-Ct binding
pocket of DnaGC. Autodock Vina software (Trott and Olson, 2010) was used for a
high-throughput analogue screen. The hits confirmed by

15

N-HSQC experiment were

used as starting point for the identification of structurally similar compounds to all four
hits described above in the ZINC database (Irwin and Shoichet, 2005). About 7700
compounds were selected for docking. The Y-shape geometry of the pocket gives
potential vectors to grow molecules (Figure 5.13).
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Figure 5.13. The pocket geometry of DnaGC with predicted orientation of L1H10 fragment. The black
arrows indicating possible vectors for compound optimisation.

Docking identified about 30 commercially available compounds with promising binding
poses and favourable binding energies. These were purchased and the binding to
DnaGC assessed using STD and 2D NMR experiments (listed in Appendix D). Some of
the compounds were not soluble in DMSO and were therefore excluded from screening.
Some of the remaining analogues had low solubility limits, therefore the highest
concentrations were either 200, 500 μM or 1 mM, depending on the compound.
The docked C4C4 fragment has good vectors for fragment growth. With the knowledge
that the tetrazole moiety might have improved membrane-crossing properties compared
with carboxylates, owing to a higher pKa, the C4C4 fragment was selected for further
development. The in silico analogue screen identified 10 tetrazole analogues (listed in
Appendix D) with favourable binding poses relative to SSB-Ct peptide. From STD and
2D NMR experiments most of the compounds obtained did not bind to DnaGC,
although 5-[2-fluoro-6-(4-fluorphenoxy)phenyl]tetrazol-1-ide (ZINC72447025) showed
an STD signal, and altered CSP in 2D NMR experiments. The NMR spectrum of this
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compound superimposed over the apo-protein spectrum is shown in Figure 5.14. The
predicted binding free energy of optimised compounds is shown in Table 5.4.

Figure 5.14. 15N-HSQC spectra of apo-protein overlayed with ZINC72447025 compound spectrum.
Green represents the apo-spectrum, magenta in the presence of 1 mM ZINC72447025 compound.

Table 5.4. The binding free energy (kcal/mol) of docked poses of first generation of fragments.

Pose 1

Pose 2

Pose 3

Pose 4

Pose 5

Pose 6

Pose 7

Pose 8

Pose 9

Pose 10

C4C4

-5.1

-5.1

-5.1

-5.0

-4.9

-4.9

-4.7

-4.7

-4.7

-4.7

ZINC72447025

-7.0

-7.0

-6.8

-6.8

-6.6

-6.1

-6.1

-6.1

-6.0

-6.0

CDS001350

-6.7

-6.7

-6.6

-6.3

-6.3

-6.2

-6.2

-6.2

-6.2

-6.2

CHEMBR7179770 -6.3

-6.3

-6.3

-6.3

-6.2

-6.1

-6.1

-6.1

-6.0

-6.0

Mapping the CSP on protein surface (Appendix C), and using that data, predicted
binding pose of ZINC72447025 compound was calculated (Figure 5.15).
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Figure 5.15. Visualisation of binding of ZINC72447025 compound. The lowest energy binding poses of
ZINC72447025 (A). Schematic representation of residues involved in interaction with compound (B).

The observed NMR peak shifts were consistent with the docked orientation (Appendix
C). The negatively charged tetrazole is predicted to form favourable electrostatic and
hydrogen bond interactions with the side chains of Lys447 and Arg452. The methyl
groups of Leu446, Met451, Leu455, Leu484 and Thr515, Leu519 form a hydrophobic
pocket accommodating two aromatic rings of the compound. One of the fluorine atoms
is about 3 Å from the amide group of Gly481, while the second one at the para-position
of the phenoxy group points out of the pocket toward Lys518. These fluorine atoms
could be involved in hydrogen bond formation with Gly481 and Lys518 (Figure 5.15).
In order to further test the docked orientation of ZINC72447025 compound 1D

19

F

NMR has been carried out in a 20-fold excess of compound. Fluorine signals were
broadened (by 0.4 Hz and 1.8 Hz respectively) and shifted slightly downfield in 1D 19F
spectra indicating the binding shown in Figure 5.16.
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Figure 5.16. 1D 19F spectra of ZINC72447025 compound at 1mM in presence (red trace) and absence (blue trace) of 50 μM DnaGC.
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The model suggested that one fluorine atom is in close proximity (3 Å) to backbone
amide hydrogen of Gly481. The most common NMR approach to gain distance
restraints are NOEs. Inter-molecular NOEs are usually observed between complexes
with tight binding (KD < 10 uM) in the slow exchange regime (off-rate of the exchange
process should be smaller than the NOE defined by the cross-relaxation rate constant)
(Neuhaus and Williamson, 1984; Vögeli, 2014). To obtain NOE-based distance
restraints, a 3D 15N-NOESY-HSQC spectrum was acquired. Where the ligand is located
less than 6 Å from backbone protons, ligand-to-protein NOEs will be observed.
However, in a weak protein-ligand interactions, because of the fast exchange between
free and bound states of protein-ligand complexes, the population of bound states was
small, therefore no protein-ligand NOEs were observed. Although the side chain region
of the spectrum had a new NOE peak, it was not assigned and unfortunately could not
be used.
15

N-HSQC experiments were used to measure the binding affinity of the first generation

of optimised hits described in section 2.2.4.7. The identified ZINC72447025 tetrazole
derivative was shown to bind to DnaGC with about 3-fold improved affinity compare to
starting C4C4 fragment, as measured by HSQC titration (1.3 mM) (Appendix E).
Binding affinities are measured by averaging among few resolved resonances in HSQC
spectra and this could lead to noticeable inaccuracies (some of the peaks in HSQC
spectra may be in different exchange rates). Additionally, limited ligand solubility,
aggregation at high concentrations often does not allow to rich the saturation during the
titration, thus resulting in underestimated KDs. Therefore, binding affinities for such
weak interactions as estimated by HSQC titration should be treated with caution
(Fielding, 2007; Lian, 2013).
Searching the ZINC database (Irwin and Shoichet, 2005) for ligands structurally similar
to ZINC72447025 indicated that the only commercially available analogue of was
CDS001350. CDS001350 is missing the halogen atoms and has para-phenoxy group
(Figure 5.17). The binding of CDS001350 to DnaGC was assessed by STD NMR
followed by

15

N-HSQC Figure 5.17A. The overlaid HSQCs of ZINC72447025

compound with CDS001350 shown in Figure 5.17B.
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Figure 5.17. (A) STD spectrum of compound CDS001350 using RCD. In red is a 1D 1H reference
spectrum, overlayed with a STD spectrum (blue). (B) HSQC spectral overlay of 15N-DnaGC with
ZINC72447025 (blue) and CDS001350 (red) at 1 mM respectively. The apo-protein spectrum is show in
black.

It was shown that compounds that possess similar binding modes to a protein will alter
the same CSPs (Medek et al., 2000). Changes in the position of phenoxy group in
87

Chapter 5: Structural and Biophysical Characterisation of Hits

CDS001350, increased the CSP magnitude (shown in the Appendix C) and showed a
slightly improved the binding affinity of KD = 1.2 mM as measure by

15

N-HSQC

titration (Appendix E).

Figure 5.18. Docked binding pose of CDS001350 (A). Schematic representation of interactions (B).

CDS001350 was docked to DnaGC as described previously and is predicted to form
electrostatic interactions with the side chains of Lys447, Thr449 and Arg452 (Figure
5.18). The central aromatic ring sits in a hydrophobic groove formed by Met451,
Leu455 and Leu484, while the oxygen atom from the phenoxy group forms a hydrogen
bond with the methyl side chain of Thr515 (Figure 5.18). In addition, the aromatic ring
of the phenoxy moiety forms a cation-π interaction with the positively charged
guanidine group of Arg452, and hydrophobic contact with the Leu446 and Trp522 side
chains.
In order to sample the impact of para-phenyl position of C4C4 fragment, additional two
commercially available compounds were purchased (Figure 5.19, compounds
CHEMBR7179770 and CHEMBR7693431). Molecular docking suggests that parasubstitutes dramatically change the orientation of the tetrazole moiety in the pocket.
STD,

15

N-HSQC experiments confirmed that replacing the fluorine atom with a larger

group massively lowers the CSP magnitude. Nonetheless, it was observed even though
the para-position of phenyl tetrazole is not favoured, addition of chlorine atom slightly
increased the CSP magnitude.
In summary the binding of C4C4 tetrazole fragment and related compounds was
explored (Figure 5.19). In silico screening identified ZINC72447025 compound with 388

Chapter 5: Structural and Biophysical Characterisation of Hits

fold improved affinity measured by HSQC titration. CDS001350 compound with
minimum structural changes showed small improvements in changing the position of
phenoxy moiety. The para-substituted analogues of C4C4 fragment showed decrease in
chemical shifts (and therefore weaker binding), which is most likely caused by
reorienting the compound in the binding pocket. Therefore binding affinities were not
measured.

Figure 5.19. Schematic representation of optimisation of C4C4 fragment. The red labelled groups were
added along the hit to lead optimisation.

5.2.6 Optimisation of Indole Scaffold
In the first generation hits, the indole scaffold was the most common structural feature.
To further explore the indole scaffold, 14 indole analogues with different functional
groups were tested (Table 5.5) (provided by Dr. Chris Hyland). A similar approach
using STD followed by 15N-HSQC experiments confirmed that most of the compounds
did not bind, or the CSPs were not significant. This indicates the importance of carboxyl
acid groups in the compounds.
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Table 5.5. Indole analogues tested for binding to DnaGC by STD and followed up by 15N-HSQC. Yindicates the binding, N-the absence of binding. Some of the compound did not show any peaks in 1D 1H
spectrum as an indicative of low solubility in experimental conditions. Y indicates positive STD while N
the absence.

Name

Structure

CH1

CH3

STD

HSQC-rank

Y

Rank 1

-

-

N

N

Y

N

-

-

Y

N

N
CH3

CH2

N
CH3

CH3

N

CH2

CH4

CH3

N

CH5

N

CH6

CH3

N
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Name

Structure
CH3

CH7

STD

HSQC-rank

N

-

Y

Rank 1

Y

Rank 1

-

-

-

-

Y

N

Y

Rank 1

Y

Rank 1

N

CH2

CH8

O
CH3

NH

CH9

N

NH

CH10
N
S

O

O

CH3

CH3

CH11

N

O

CH12
N

CH13

O
CH3

N
CH3

CH14

N

N
CH3
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5.3 Conclusion
The first generation of hits were investigated by protein-based NMR (15N-HSQC),
which also demonstrated that the binding site was identical to the peptide-binding site.
The binding affinities were measuring using HSQC titration experiments. For
fluorinated compounds such as C4C4, the binding was confirmed by 1D

19

F NMR. In

silico CSP-guided docking approach was utilised to identify likely the binding
orientations of hits.
In silico fragment-to-hit approach was utilised for an analogue screen. 7700
commercially available compounds from ZINC database were docked into the SSB-Ct
pocket of DnaGC. The compounds with best score were purchased and tested for
binding (STD, HSQC). Two tetrazole derivatives with improved affinities were
identified. The ZINC72447025 compound was unsuccessfully used to gain the NOEdriven distance restrains.
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6.1.1 Introduction
Paramagnetic NMR is an alternative to traditional NOE-based experiments for solving
structures (Keizers and Ubbink, 2011; Otting, 2010). Paramagnetic ions are able to
weakly align biomolecules along the external magnetic field vector, generating distance
restraints (Otting, 2008). By attaching a paramagnetic center to a protein via tags makes
it possible to apply the method not only to solving structures of protein-protein
complexes, but also determining protein structures in complex with ligands.
Paramagnetic entities include organic radicals (e.g. nitroxide radicals) and metal ions
(e.g. Mn2+, Gd3+) with unpaired electrons. Paramagnetism is generated as a result of
interactions between the unpaired electrons in the 4f orbitals of lanthanides and the
nucleus of interest (Su et al., 2006). Organic radicals affect the relaxation properties of
proteins (they increase the longitudinal and transverse relaxation rates). The change in
relaxation rates between paramagnetic and diamagnetic samples is known as
paramagnetic relaxation enhancement (PRE) (Figure 6.1). PRE is responsible for line
broadening in NMR spectra, and its effect on line width is proportional to the inverse
sixth power (1/r6) of distance between paramagnetic centres and nuclei (Otting, 2008).
PRE can be used to measure distances of up to 30 Å in proteins and detect
conformational changes (Clore et al., 2007).
Paramagnetic lanthanide tags enable the measurement of pseudocontact shifts (PCSs)
and residual dipole couplings (RDCs) (Otting, 2008). PCS can be described by the
magnetic susceptibility tensor χ defined in terms of three orthogonal axes (χx, χy, χz)
(Otting, 2010). If the magnetic moment of the paramagnetic center changes with
different orientations of the centre in the magnetic field, the χ tensor is anisotropic. The
χ tensor can be decomposed into isotropic and anisotropic components. The anisotropic
component (Δχ) can be expressed in axial and rhombic components (Δχax = χz − (χx +
χy)/2 and Δχrh = χx − χy). Pseudocontact shifts ΔδPCS arise from those components as
follows (Eq. 6.1):
𝛥𝛿 𝑃𝐶𝑆 =

1
3
2
(3𝑐𝑜𝑠
[𝛥𝜒
𝜃
−
1)
+
𝛥𝜒 𝑠𝑖𝑛2 𝜃𝑐𝑜𝑠2𝜑]
𝑎𝑥
12𝜋𝑟 3
2 𝑟𝑥

Equation 6.1. Δχax and Δχh are the axial and rhombic component of Δχ: r, θ and φ are the polar
coordinates of the nuclear spin in respect to the principal axes of Δχ (Bertini et al., 2002).
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This relationship has been used to solve solution-state protein structures (Yagi et al.,
2013), structures of protein-protein complexes (Hass and Ubbink, 2014) and in drug
discovery for solving the structure of small-molecule protein complexes (John et al.,
2006; Guan et al., 2013; Pintacuda et al., 2007). In addition to PRE, RDC and PCS, the
presence of a paramagnetic centre in a structure results in Curie-dipolar cross-correlated
relaxation (CDCCR) effects. While a comprehensive description of RDC and CDCCR
are beyond the scope of this thesis, the effects of PRE and PCS shown in Figure 6.1 can
be exploited to characterise structure and function of biomolecules. Paramagnetic NMR
was initially used to study proteins with metal-binding sites. Efforts to develop new
methods have extended its applicability to include proteins without native metal-binding
sites can be studied through introduction (by site-directed mutagenesis) of solventexposed cysteine residues and the subsequent covalent attachment of tags containing
paramagnetic ions. For readily interpretable PCSs, the paramagnetic tag must be rigid
relative to the protein (Shishmarev and Otting, 2013). Flexibility of the tag will reduce
the intensity of PCSs and different tag locations may need to be trialled to optimise
rigidity.

95

Chapter 6: Structural Determination of Protein-Ligand Complexes

Figure 6.1. Paramagnetic effects caused by presence of tags attached to the protein. Top figure represents
the magnitude of measured paramagnetic effect of one and three tags. Bottom figure highlights changes
resulted by PRE and PCS in the recorded HSQC spectra. PRE gives peak intensity changes (on the
bottom left) whereas the PCS causes chemical shifts and in some cases similar effect to PRE.

The main difference between PRE and PCS is that PRE gives distance restraints from
the paramagnetic centre, while PCS possesses additional angular dependence relative to
the paramagnetic tag (Koehler and Meiler, 2011). The PCS effect varies by a factor of
1/r3 with distance (r) between the paramagnetic centre and the nucleus of interest and
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hence can be used to measure long-range distances compared with PRE. It has been
shown that, the case of the dysprosium (III) ion, PCSs are capable of measuring
distances up to 40 Å from the paramagnetic centre to a nucleus of interest (Allegrozzi et
al., 2000; Pintacuda et al., 2007).

6.1.2 Aim
Determination of DnaGC structures in complex with hits using paramagnetic NMR. To
test the binding of compounds to other SSB-Ct binding partners (E. coli and A.
baumannii χ subunit of Pol III, PriA and RNAse HI).

6.2 Results and Discussion
6.2.1 Paramagnetic NMR experiments
6.2.1.1 Preparation of lanthanide tagged DnaGC
In order to apply paramagnetic methods, the protein of interest must first have a metal
binding site, or alternatively solvent exposed cysteine residues. In order to accurately
orient the Δχ tensor, at least three tags are required at different positions relative to
targeted binding site (Koehler and Meiler, 2011; Yagi et al., 2013).
Previous studies showed that T499C, E532C and D537C mutants of DnaGC have poor
expression levels (Dr. Karin Loscha personal communication), therefore new positions
were chosen. The positions of new cysteine residues relative to SSB-Ct binding site is
shown in Figure 6.2. The position of cysteine mutants were chose to be within 10 to 30
Å distance from SSB-Ct binding pocket of DnaGC. The Q445C, E517C and S545C
mutants were cloned (by Dr. Nan Li) and expressed in
described for 15N-labelled DnaGC in section 2.2.1.7.
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Figure 6.2. Positions of three residues mutated to cysteine relative to SSB-Ct binding pocket.

Unfortunately, purification of the S545C mutant of DnaGC failed, as the protein was
inseparable from other E. coli proteins. The other two mutants had relatively low
expression level. The cysteine mutants were designed such that the introduced cysteine
side chains would be solvent exposed and thus would need to be maintained in a
reduced state. Therefore, the samples were treated with excess of DTT (5 mM) in order
to protect them from oxidisation. Prior to tagging the protein with a paramagnetic
complex, the excess DTT was dialyzed out with NMR buffer as described in section
2.2.4.10.
The diamagnetic (C2Y3+) and paramagnetic tags (C2Tm3+, C2Tb3+) (Figure 6.3A) were
applied to two of the DnaGC mutants as described in section 2.2.4.10.
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Figure 6.3. Chemical structure of C2 and THP (S) tags.

The ligation efficiency of paramagnetic tags is very high, and after overnight
incubation, the proteins were expected to be fully ligated.

6.2.1.2 PCS Measurements
Lanthanide induced PCSs are measured by recording

15

N-HSQC spectra.

15

N-HSQC

was recorded for both C2-tagged Q445C and E517C mutants. The Q445C mutant did
not produce significant PCSs, possibly as a result of flexibility of the tag, whereas
E517C mutant shows distinct PCSs (Figure 6.4).
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Figure 6.4. 15N-HSQC overlay of C2-tagged E517C mutant containing diamagnetic Y 3+ (black), Tm3+
(blue) and Tb3+ (red) respectively.

PCSs were evaluated for only 1H spin to minimise residual anisotropic chemical shifts
due to smaller chemical shift anisotropy (John et al., 2005). PCSs were calculated by
subtracting the observed diamagnetic chemical shifts from paramagnetic (Table 6.1).
Table 6.1. Calculated PCSs of 15N-labelled E517C DnaGC measured with C2 tag. Values are in ppm.

Residue

Tm3+

Tb3+

Residue

Tm3+

Tb3+

Gly438

-0.08

0.09

Gly483

0.09

-0.15

Arg441

-0.13

0.04

Leu484

0.17

Met451

-0.11

-

Arg486

0.13

-0.15

Leu457

-0.08

0.1

Leu504

-0.05

0.06

Leu471

-0.06

0.01

Gly509

0.11

-0.14

Asn473

0.1

-0.04

Thr510

-0.02

0.02

Lys478

-0.14

0.01

Asn512

-0.05

0.06

Leu479

0.05

-0.07

Thr515

-0.03

-

Gly481

0.2

0.2

Asp523

0.24

-0.25

Leu482

-0.04

0.1

Glu558

-0.06

0.05
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Residue

Tm3+

Tb3+

Residue

Tm3+

Tb3+

Thr560

-0.03

0.01

Asn565

-0.05

0.05

Gly562

-0.02

0.02

Glu566

-0.08

0.09

Ser564

-0.06

0.08

Leu574

0.08

-

Numbat software (Schmitz et al., 2008) was used to fit the Δχ tensor to the structure of
DnaGC/SSB-Ct (Tak Lo, 2012) using Eq. 6.1 (Bertini et al., 2002). Substantial spectral
overlap in the 7.6-8.6 ppm (1H) region decreased the possibility of unambiguous
assignment of the peaks. Nonetheless, about 25 well-resolved peaks were used for
calculations.
Subsequently, DQF-COSY, HMBC spectra were acquired and assigned for the
CDS001350 compound (data not shown). In order to observe PCSs altered by
CDS001350 binding to DnaGC, the compound was mixed with C2-tagged E517C
mutant in a 4:1 molar ratio and 1D 1H spectra were recorded with diamagnetic and
paramagnetic labels (Figure 6.5).

Figure 6.5. 1D 1H spectra of CDS001350 compound at 1 mM (A), with C2Y 3+-tagged (B) and C2Tm3+tagged (C) E517C DnaGC.
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1D 1H spectra for the diamagnetic sample gave well-resolved peaks with few additional
peaks (Figure 6.5B). Extra signals were most likely a result of a residual amount of free
tag or other chemical impurities from the tag preparation. 1D 1H spectra were recorded
with the same molar ratio of CDS001350 to C2Tm3+-labelled DnaGC. Unfortunately
two broad peaks were detected with low spectral resolution (Figure 6.5C). Severe line
broadening can be explained by a large PRE effect of the C2-tag.
Subsequently, a new tag, THP was tested (Figure 6.3B). The (R), (S)-THP tags were
ligated as described for the C2-tag. 15N-HSQC was acquired for (S)-THP-tagged E517C
mutant of DnaGC. The protein showed PCSs: about 10 peaks were unambiguously
assigned (data not shown). The same 4:1 ligand-protein ratio with CDS001350
compound was used for measuring PCSs for the compound. To eliminate false positives
caused by non-specific tag-inhibitor interactions, a 1D 1H NMR spectra of tag plus
CDS001350 at a 1:4 ratio was recorded (Figure 6.6).

Figure 6.6. 1D 1H spectra showing CDS001350/(S)-THP tag interaction. (A) 1D 1H spectrum (green) of
CDS001350 compound at 1 mM, (B) 1:4 ratio mixture of CDS00135/(S)-THP. Blue spectrum represents
paramagnetic (Tm3+), red is diamagnetic (Y3+) respectively.

Surprisingly, CDS001350 in the presence of (S)-THP-tag showed undesirable nonspecific interaction, demonstrated by comparison of chemical shifts in 1D 1H NMR
spectra (Figure 6.6). Due to the interactions of tag with inhibitor, it was not possible to
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use PCS for structural calculations. The most likely explanation for this interaction is
the electrostatic attraction between the positively charged tag and the negatively
charged tetrazole ring. The lack of negatively charged tags is a current limitation of the
method.

6.2.1.3 Paramagnetic Relaxation Enhancement
The Q445C mutation is located relatively close to the SSB-Ct binding pocket, enabling
the possibility of PRE-NMR experiments. The residues close to the tag, including the
ligand, will experience a strong paramagnetic effect even if the life time of the state is
short (Volkov and Worrall, 2006). The most common method for utilizing the PRE
effect is through the introduction of a nitroxide spin label. MTSL is the most popular
such label, as it has high selectivity for cysteine thiols.
The Q445C mutant was labelled with MTSL (described in 2.2.4.10) and 1D 1H spectra
were recorded in presence of CDS001350 compound at 1:4 and 1:6 molar ratio with
MTSL (paramagnetic) and reduced MTS (diamagnetic) samples (Figure 6.7).
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Figure 6.7. At top is shown the reduction reaction of MTSL to MTS. Below are shown 1D 1H PRE
measurements with MTSL labelled Q445C DnaGC mutant with CDS001350 compound at 1:6 (A) and
1:4 (B) molar ratio. Red and blue spectra indicate paramagnetic, green and magenta diamagnetic samples
respectively.

Two different concentrations of MTSL/MTS labelled samples were used in an attempt
to exclude random intermolecular interactions by showing a consistent PRE effect.
However, in both cases, line broadening to the same extent was observed (Figure 6.7).
The PRE effect was evenly distributed for all CDS001350 signals, thus makes PRE did
not yield useful information. The limited precision of PRE can be explained by the
flexibility of the MTSL group and the small molecular size of the inhibitor compared to
the protein.
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6.2.2 Phenylalanine moiety as a starting point
As described earlier, SSB is a protein interaction hub known to bind more than 14
different proteins involved in various stages of replication, repair (Shereda et al., 2008).
One such protein is ExoI, 3’ to 5’ exonuclease. Recently the crystal structures of
compounds disrupting the ExoI/SSB-Ct interaction were identified using a HTS
approach:
phenylpropanic

(Z)-2-(5-(3-bromobezylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3acid

(BOTP),

thioxothiazolidin-3-yl)-2-phenylacetic

(E)-2-(5-(2-methyl-3-phenylallyl)-4-oxo-2acid

(MPTA),

2-((2-chloro-5-

(trifluromethyl)phenyl)amino)-5-methoxybenzoic acid (CFAM) and 5-(tert-butyl)-2-(6chlorobenzo[d]thiazole-2-yl)-2,4-dihydro-3H-pyrazol-3-one (BCBP) (Figure 6.8) (Lu
et al., 2010).

Figure 6.8. Chemical structures of inhibitors of interactions with the C-terminus of SSB.

Furthermore, the inhibitors were tested with other SSB-Ct binding partners (RecQ,
PriA) and binding was also observed (Lu et al., 2010). FP competition assays
demonstrate that these compounds bind competitively to DnaGC in competition with
SSB-Ct. The binding of these compounds was determined using fluorescent polarisation
(FP) competition assay (Luzuriaga, 2011). The crystal structures of ExoI with bound
inhibitors revealed that part of the compounds mimic the Phe177 residue of SSB-Ct (Lu
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et al., 2010). In order to study the interaction with DnaGC, 2D

15

N-HSQC NMR

experiment was utilised (Figure 6.9).

Figure 6.9. BOTP docked into DnaGC. (A) Lowest energy binding pose of BOTP in complex with
DnaGC, generated by docking. (B) The spectral overlay of apo-protein (black) and in the presence of
1mM BOTP (blue).
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Using the method described in Chapter 5, BOTP (1 mM) was added to

15

N-labelled

DnaGC and 2D 15N-HSQC spectrum was recorded. Addition of the compound result in
loss of peaks, demonstrating that the interaction was in intermediate exchange
(Williamson, 2013).
In all currently available crystal structures of SSB-Ct with binding partners, and in MD
simulations described in Chapter 3, the side chain Phe177 forms hydrophobic
interactions with the various binding pockets while the carboxylic acid motif forms
strong electrostatic/hydrogen bond interaction with a basic residue. The possibility of
using phenylalanine as a starting point for fragment-to-hit optimisation was therefore
considered. Based on experimental and in silico data, N-Acetyl-L-phenylalanine was
tested using STD and by a subsequent

15

N-HSQC experiment. Both experiments

confirmed binding, although CSP magnitudes compared to other fragment was
significantly weaker, inferring that binding affinity is weaker.

15

N-HSQC titration

experiments were conducted. The measure binding affinity was about 2-fold weaker
compare to the fragment hits (KD ~ 6 mM). Similar to the method described in Chapter
5, the analogue screen performed by molecular docking using ZINC Database identified
N-Phenylacetyl-L-phenylalanine, which was tested (Figure 6.10).

Figure 6.10. Spectral overlay of DnaGC with N-A-L-Phe and N-PheA-L-Phe. 2D spectra for the apoprotein (black), protein plus N-A-L-Phe (red) and protein plus N-APhe-L-Phe (blue) are shown.
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The

15

N-HSQC spectra for N-Phenylacetyl-L-Phenylalanine showed greater CSP-

magnitudes compare with N-Acetyl-L-phenylalanine, although no dramatic changes
were detected.
Observations made here complemented with available structural data indicating that
phenylalanine derivatives could be used to develop inhibitors of SSB-Ct interactions.

6.2.3. Binding of DnaGC Inhibitors to Other SSB-Ct Binding Partners.
In order to explore the possibility that hits against DnaGC could bind to other SSB-Ctbinding partners, fragment hits were tested for binding to SSB-Ct binding partners from
E. coli and A. baumannii. These were E. coli Pol III χ, PriA, RNAse HI and A.
baumannii Pol III χ (E. coli χ subunit of Pol III, PriA, RNAse HI were generously
provided by Dr. S. Jergic and Dr. N. Li). Binding was assayed using STD-NMR
(Figure 6.11).

Figure 6.11. STD-NMR of L1G8 fragment with other SSB-Ct binding partners represented in different
colours: black-1D reference spectrum, green-E. coli Pol III χ, yellow-A. baumanni Pol III χ, dark greenRNAse HI and red-PriA respectively.

Remarkably, STD experiments showed binding of four fragments (L1G8, L1H10, C4C4
and L1A11) to the four SSB-Ct binding partners considered here. Additionally, the first
generation of tetrazoles were tested and binding was confirmed (Appendix F). The best
108

Chapter 6: Structural Determination of Protein-Ligand Complexes

fragments hits were docked into E. coli Pol III χ using the method described in 2.2.4.8.
The resulting binding free energies are shown in Table 6.2. The predicted binding
orientations of C4C4 and ZINC72447025 to E. coli Pol III χ are shown in Figure 6.12.

Table 6.2. The binding free energy of docked poses of first generation of fragments generated by
Autodock Vina for E. coli χ.

Pose 3

Pose 4

Pose 5

Pose 6

Pose 7

Pose 8

-5.9

-5.8

-5.5

-5.5

-5.5

-5.5

-5.4

-5.4

-5.4

L1G8

-6.4

-6.4

-6.2

-6.1

-6.1

-6.1

-6.0

-6.0

-5.9

-5.8

L1H10

-5.7

-5.7

-5.6

-5.5

-5.5

-5.5

-5.4

-5.3

-5.3

-5.3

L1A11

-5.2

-5.

-5.2

-5.2

-5.1

-5.1

-5.1

-5.1

-5.1

-5.1

ZINC72447025 -6.8

-6.8

-6.6

-6.4

-6.4

-6.4

-6.4

-6.3

-6.3

-6.2

-6.7

-6.7

-6.7

-6.7

-6.7

-6.6

-6.6

-6.8

-6.5

-6.5
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Figure 6.12. Lowest energy orientation of C4C4 (A) and ZINC72447025 (B) compounds with E. coli χ.
Protein is shown in ribbon coloured in yellow. Residues within 5 Å away from ligand are represented in
stick.
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For the docked E. coli χ/C4C4 complex, three basic residues (Arg128, Lys132 and
Arg135) are predicted to interact with the negatively charged tetrazole group, while the
phenyl group forms a π-π stacking interaction with Tyr131. The fluorine atom of C4C4
interacts with the side chains of Leu8, Ala117 and Thr143 (Figure 6.12A). In case of
ZINC72447025, the position of the tetrazole group is rotated about 45° in the model
(Figure 6.12B). Small rearrangements in the binding pose bring the tetrazole group
closer to Arg128 and Lys124. The fluorine atom in the ortho-position makes contact
with backbone carbonyl group of Lys124. The phenyl ring forms a σ-π interaction with
the methyl groups of Leu8 and Ala117. The phenyl ring of the extended phenoxy
moiety forms a π-π stacking interaction with Tyr131, positioning the fluorine in close
proximity to the hydroxyl group of Tyr131 and side chain of Arg135. The docked
models suggest that the fluorine atoms in both C4C4 and ZINC72447025 compounds
are involved in various interactions. 1D

19

F NMR would agree with the hypothesis

based on model. 1D 19F spectra recorded in the presence of a 20 molar excess of ligand
were acquired with E. coli χ. In 1D

19

F spectra of C4C4 fluorine peak broadened and

shifted slightly upfield (Figure 6.13A).
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Figure 6.13.19F-NMR of C4C4 (A) and ZINC72447025 (B) compound in isolation (blue) and with E. coli χ in presence of protein at 1:20 protein-ligand ratio (red).
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1D

19

F experiments were conducted under the same experimental conditions for

ZINC72447025/E. coli χ and showed similar downfield peak shifts and intensity
changes as for DnaGC. Experimentally, these results support the predicted binding
models.
A comparison of binding poses of all three tetrazole derivatives with E. coli χ suggests
that the position of the tetrazole moiety may be different in ZINC72447025, moving
away from Lys132 and Arg135 towards Lys124, with Arg128 maintaining its
interactions. With respect to compound CDS001350, changing the position of the
phenoxy-group is predicted to affect the orientation of the compound in the pocket, with
the tetrazole returning to a position similar to that observed for C4C4 (Figure 6.14).

Figure 6.14. Comparison of modelled orientations of C4C4 fragment and two best tetrazole analogues in
the SSB-Ct binding pocket of E. coli χ. Protein shown in yellow ribbon, C4C4 in green, ZINC72447025
is in violet and CDS001350 fragment is shown in red.

6.3 Conclusion
Paramagnetic NMR was attempted as an alternative method for obtaining distance
restraints to characterise for protein/ligand interactions. A PCS-based approach was
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taken. Unfortunately non-specific compound-tag interactions were observed. PRE NMR
did show changes in relaxation of the fragment, however, these were evenly distributed
across the fragment signals, and thus did not yield useful spatial data. Intriguingly,
compounds did show binding to other SSB-Ct binding partners: E. coli Pol III χ, PriA,
RNAse HI and A. baumannii Pol III χ.
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7.1 Conclusion
The identification of new classes of broad-spectrum antibiotics acting via new targets is
of great importance. The rise of so-called “superbugs”, i.e. antibiotic resistant infectioncausing bacteria-poses a potentially catastrophic threat to public health. The rise of
multi- and pan-resistance coincides with an “innovation gap”: only two new classes of
broad-spectrum antibiotics have been approved in the last 40 years: the oxazolidinones
and the lipopeptide antibiotic daptomycin. Almost all classes of modern antibiotics are
derived from chemical scaffolds based mostly on natural products discovered over 40
years (Cole, 2014).
The DNA replication machinery is a rich source of targets for antibiotic discovery
(Sanyal and Doig, 2012; Robinson et al., 2012). SSB is known to interact with more
than 14 binding partners through its C-terminus (Shereda et al., 2008; Tak Lo, 2012;
Ryzhikov et al., 2011; Lu and Keck, 2008; Marceau et al., 2011). Simultaneously
disrupting interactions of the SSB C-terminus with multiple binding partners has the
potential to neutralise bacterial pathogens. The human SSB C-terminus is distinctive
and therefore inhibitors of bacterial SSB-Ct interactions are unlikely to react with
human SSB-Ct-binding partners (Robinson et al., 2010).
The SSB-Ct can be described as a “short linear motif” or SLiM. SLiMs are short,
conserved motifs involved in many vital processes in the cell (e.g. cell proliferation,
signalling). The structures of SLiMs are generally not well characterised mainly due to
their disordered nature. SLiMs are often in transient contact with their binding partners.
Upon binding, some of them become structured. SLiMs have been found to play an
essential role in pathogens (e.g. virus host cell interactions, they tend to mimic host cell
SLiMs) (Kadaveru et al., 2008; Davey et al., 2011; Yang, 2012). Advances have been
made targeting SLiM-mediated interactions in recent years (Wells and McClendon,
2007). Some of these compounds are in clinical trials. For example, Cilengitide (a
cyclized Arg-Gly-Glu-containing pentapeptide) targets a SLiM binding site in the
treatment of gliomas. Cilengitide selectively blocks binding of integrins αvβ3 and αvβ5
to Arg-Gly-Asp motifs in the extracellular matrix. Inhibition prevents signalling and
causing the disassembly of the cytoskeleton in glioma cell (Scaringi et al., 2012). A
second example is Nutlin-3, an inhibitor of the MDM2/p53 interaction (Secchiero et al.,
2011). MDM2 binds a short hydrophobic motif in the N-terminal domain of p53, and
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nutlin-3 blocks the SLiM binding site on MDM2, leading to p53 stabilization and
activation of cell cycle arrest and apoptosis in cancer cells.
Currently there are four crystal structures of SSB-Ct (or segments of it) in complex with
its binding partners: DnaGC (Tak Lo, 2012), RecO (Ryzhikov et al., 2011), ExoI (Lu
and Keck, 2008) and the Pol III χ/ψ subunits (Marceau et al., 2011). In all structures Nterminii of the SSB-Ct peptide has high B-factor, and was not detected in electron
density. Molecular dynamic simulations of four SSB-Ct binding partners DnaGC,
RecO, Exo I and Pol III χ/ψ subunit in complex with SSB-Ct were computed. The
simulations shed light on similar features of SSB-binding pockets and in the dynamic
behaviour of bound SSB-Ct. Critical features that could be exploited in drug design
were identified. It was observed in all systems that the three hydrophobic residues (the
IPF sub-motif) at the C-terminus were relatively rigid, while the three contiguous
aspartate residues (the DDD sub-motif) were flexible. Positively charged residues were
identified on the surface of binding partners that engaged in electrostatic interactions
with the aspartate residues of SSB-Ct. All crystallographically observed interactions
were maintained in the MD simulations. In all complexes considered, a salt bridge
occurs between the SSB-C terminal carboxylic acid and an arginine side chain. The
impact of these positively charged resides were in agreement with mutagenesis data.
The local dynamics of SSB-Ct was assessed by residue-based RMSD and order
parameter calculations. The SSB-Ct peptides showed fluctuations that increased with
distance from the C-terminus. These were in agreement with weighted atomic density
and order parameter calculations, indicating that in all cases, the three contiguous
aspartate residues do not bind in a specific pocket and are disordered. The IPF sub-motif
is more stable, rigidly bound and engages in specific interactions. Clustering analysis
indicates that there are highly populated clusters in the DnaGC and RecO simulations,
and low-population clusters in ExoI and χ/ψ simulations. In silico mutagenesis of
Ile175Leu and three aspartate residues to asparagine (Asp173Asn, Asp174Asn and
Asp174Asn) in SSB-Ct have shown that the loss of charged residues in the DDD submotif destabilizes SSB-Ct-binding. These along with existing mutagenesis studies
emphasise the importance acidic residues in the SSB-Ct peptide.
One particular SSB-Ct binding partner, DnaG primase was subjected to fragment
screens to find fragments that could act as starting points for antibiotic development.
Initially, attempts were made to use X-ray crystallography for fragment screening.
However, good quality crystals of neither DnaGC (nor RCD) were obtained. NMR and
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SPR-based methods were therefore utilised. Fragment-based screening against DnaG
primase targeting the DnaGC/SSB-Ct interaction was successful. Two fragment
libraries were screened against DnaG primase using various biophysical techniques
(summarised in Figure 7.1).

Figure 7.1. Summary of screening workflow. Two fragment libraries were used for primary screening.
Identified hits were confirmed by 15N-HSQC.

The Zenobia Therapeutics “first pass screen” was screened using a SPR competition
assay. Fragments competed with immobilized biotinylated SSB-Ct peptide on the SPR
chip surface for the peptide-binding pocket on DnaG primase. Six compounds (A9,
B10, C4, D6, D8 and C1) were identified that competed for occupying the SSB-Ct
binding site on DnaGC. SPR hits were validated by STD-NMR. A second fragment
library, the Monash Institute of Pharmaceutical Science fragment library (1132
fragments), was screened against RCD using STD-NMR. The STD signal intensity was
used to rank the compounds. STD-NMR gave 17% hit rate (200 fragments). The high
hit rate can in part be explained by non-specific binding to the protein surface,
compound aggregation in the cocktail mixtures and the presence of two domains in the
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RCD construct provides a greater surface area for fragments to bind to. STD hits were
ranked according to their signal intensity.
Fragments known to be non-specific binders (“frequent hits”) were excluded from the
candidate compound list. 2D 1H-15N HSQC was used to filter the remaining rank 3 and
2 hits for those binding to DnaGC. Some optimisation was carried out to improve the
HSQC experimental conditions, modifying the buffer that was used in all
measurements. CSP magnitude was used to rank the compounds. Based on STD signal
intensities and CSP magnitude changes in the HSQC experiments, hits from the MIPS
library were more potent compare to SPR hits. The carboxylic acid group was common
functional group in identified fragments. It was shown for some of the compounds (e.g.
L1C6) and indole scaffold that the presence of a carboxylic acid moiety in the
compounds is necessary.
The binding orientations of hits were generated by experiment-driven (CSP-guided)
molecular docking using Autodock Vina 1.1.2. Thus predicted binding poses were in
agreement with experimentally observed chemical shift perturbations. For fluorinecontaining ligands, 1D 19F-NMR was employed. Peak shift and intensity changes were
observed upon addition of DnaGC to the ligand, providing further evidence in support
of the predicted binding poses. The predicted binding site of the fragments is in
occupying the IPF-binding pocket of DnaGC.
Five fragments (C4C4, L1G8, L1H10, L1A11 and L-phenylalanine) were selected for
fragment-to-hit optimisation, all having millimolar binding affinity to DnaGC. In all
five fragments there is a carboxylic acid motif (except C4C4, which contains a tetrazole
group) and hydrophobic aromatic ring. Binding affinities were estimated using

15

N-

HSQC titration. High throughput in silico docking was used to screen the ZINC library
for commercially available analogues of the fragment hits. Overall 7700 compounds
were docked into the DnaGC pocket. 30 analogues of first generation of hits were
purchased for testing the binding to DnaGC. A series of phenoxy tetrazole derivatives
were identified with 2-fold improvement in binding affinities: ZINC72447025 (KD 1.3
mM) and CDS001350 (KD 1.2 mM). Calculated binding orientations suggest that
Arg452 is crucial to the binding of the tetrazole moiety via a salt bridge interaction. 3D
15

N NOESY-HSQC was carried out on one such compound, ZINC72447025 with the

aim of generating models of the bound compound guided by NOE-based distance
restraints. Due to the high micromolar affinity compound, no protein to ligand NOEs
were observed.
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Paramagnetic NMR methods were then explored as an alternative approach to obtain
distance restrains. Three DnaGC cysteine mutants (Q445C, E517C and S545C) were
designed and cloned. Two (Q445C, E517C) were successfully expressed and purified.
Two different experiments were carried out monitoring PCSs and PRE changes. For the
PCS measurements, two lanthanide tags (C2 and (S)-THP) were tested. The C2 tag
caused extensive line broadening therefore (S)-THP was used. PCSs for

15

N-DnaGC

and CDS001350 compound were observed, however, non-specific tag-compound
interactions contributed to overall PCSs, rendering the data unusable. Non-specific tagcompound interactions may be attributed to electrostatic attraction between the positive
charges on the tag and negatively charged tetrazole moiety in the compound.
Paramagnetic relaxation enhancement experiments were attempted as a last resort.
MTSL-paramagnetic tag was attached to Q445C mutant of

15

N-DnaGC for PRE

experiments. Two concentrations of MTSL-labelled DnaGC with CDS001350
compound were used to measure the intensity changes for paramagnetic (MTSL) and
diamagnetic (MTS) samples, however, the PRE effects on the compound signals were
evenly distributed. This is likely due to high flexibility in the MTSL tag.
Five of the first generation hits, along with two optimised tetrazole derivatives were
tested for binding to four other SSB-Ct binding partners (E. coli χ, PriA, RNAse HI and
A. baumannii χ) using ligand-based NMR experiments. All tested compounds have
shown binding to similar extent to DnaGC.

7.2 Future Directions
The results presented here provide insights into SSB-Ct interactions and SSB-Ct
binding sites as drug targets. Based on the similar patterns behaviour of SSB-Ct in MD
simulations presented in Chapter 3, the design of multi-target inhibitors of SSB-Ct
binding may be possible. HTS approaches have identified inhibitors of the ExoI/SSB-Ct
interaction (Lu et al., 2009). Four compounds were identified (BOTP, MPTA, BCBP
and CFAM) that have a phenylalanine-like motif in their structure and bind to RecO,
PriA. However further experiments conducted on the effects of these compounds in
Bacillus subtilis species was due to off-target activity, affecting protein synthesis
(Marceau et al., 2013).
MD simulations carried out in this work indicated that SSB-Ct binding partners have
similar structural features. Therefore, compounds identified by Lu and co-workers could
be co-crystallised with other SSB-Ct binding partners to elucidate the three-dimensional
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structure of the complexes, that could help in structure-guided optimisation of
compounds for multi-target binding.
A major drawback in this project was the lack of robust crystals for determination of
three-dimensional structures of DnaGC/ligand complexes. Future work could explore
the crystallisation of homologues of DnaGC and/or RCD from different species other
than E. coli. Recently, the crystal structure of the DnaG C-terminal domain from Vibrio
cholera was deposited in the PDB (PDB ID 4IM9; Abdul Rehman, Tarique and
Gourinath). This protein shows 42% sequence identity with respect to E. coli DnaGC,
the SSB-Ct binding site is conserved, and the SSB-Ct binding site is not blocked by
crystal contacts. It should be noted that the C-terminal 6 residues of V. cholera SSB are
identical to those in E. coli, i.e. DDDIPF. Once SSB-binding to V. cholera DnaGC is
confirmed, this crystal form could be useful for determining structures of complexes
with the compounds reported here. Also, new cysteine mutants could be produced for
further paramagnetic NMR experiments. New paramagnetic tags (e.g. CLaNP-5)
(Keizers et al., 2008) are becoming available that have been proven to be more reliable
compare to single-armed tags.
The compounds described in this thesis that bind to DnaGC represent a starting point
for the development of tighter-binding ligands. This may be achieved by optimisation of
the tetrazole scaffold. This could involve extending the best compound (CDS001350) to
more fully occupy the SSB-Ct binding site on DnaGC. Alternatively, optimisation of
indole scaffold could provide an additional approach. Thermodynamic profiling of
compounds using isothermal titration calorimetry will assist in future optimisations by
quantifying the entropic and enthalpic contributions to binding. Eventually, in vivo
functional assays and estimates of antibacterial activities will be conducted on
optimised analogues to asses their activity in vivo.
Finally, some of the compounds identified from the STD-NMR screen potentially bind
to the RPD domain of DnaG primase. Additional experiments are needed in order to
confirm that these compounds bind to RPD and that they do so in a manner that could
inhibit RNA polymerase activity. Available crystal structure of E. coli and S. aureus
species RPD domains indicate high structural similarity (Rymer et al., 2012; Mansfield
and Dixon, 2012). Therefore, potentially, these structures could be used for inhibitor
design.
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Appendix A. Backbone RMSD plotted for each individual chain of RecO/SSB-Ct, χ/SSBCt and ExoI/SSB-Ct systems along the 100 ns MD simulations. (A) represents RMSDs
for the entire RecO/wtSSB-Ct complex (black), RecO/DDDLPF (red), and
RecO/NNNIPF (blue) mutated systems, (B) is RMSD for the SSB-Ct peptides from
RecO/SSB-Ct complex. (C) represents χ/ψ-SSB-Ct complex, where the complex is in
green, χ in red, psi in blue and SSB-Ct in black, (D) Black is ExoI/SSB-Ct complex
(black), red is ExoI and blue SSB-Ct respectively.
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Appendix B. List of compounds identified as STD rank 2 and rank 3.
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O
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H
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NH
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H2N

N
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Cl

3-chloro-4-(1HD2

193.63

C9H8ClN3
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3-methyl-6(thiophen-3-yl)-
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N
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N
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NH
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N
NH 2

O
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ife3
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C9H9N3O2

methoxyphenyl)1,3,4-oxadiazol-
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O
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N
H2N

O
S

2011_L
ife2

S
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benzothiazole-6sulfonamide

NH 2

177

MIPS0000361

Appendices

Structure

Plate

Plate

Mol

name

well

weight

Formula

LogP

Rotatabl

Molecule

e bonds

name
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1(9),2,5,7tetraen-5-amine
O
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H2N

N
H
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HN

3-cyclopropylG1
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1H-pyrazole-5carbohydrazide

N
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NH 2

NH
HN
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Cl
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NH 2

OH
OH
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ife4

NH

4-hydroxy-1HB4
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C9H7NO3

indole-2carboxylic acid

MIPS0000518

O
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O

O

N
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CH3
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1
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0.96

3

imidazole-2-

NH
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thione
H2N

O
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N
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N

N
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S
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carboxamide
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O
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4-phenyl-1,2,5G5
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OH
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S
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C10H11N3O2
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)-1,3,4-thiadiazol2-amine

181

MIPS0001410

Appendices

Appendix C. A CSP plots altered by addition of (A) L1G8, (B) L1H10, (C) L1A11, (D)
C4C4, (E) ZINC72447025 and (F) CDS001350 compounds monitored by 15N-HSQC.
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Appendix D. The list of purchased fragment analogues that did not bind to DnaGC.
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CH3

Appendix E. Binding affinities measured by HSQC titration of (A) ZINC72447025 and
(B) CDS00135 compounds. Different curves corresponds to perturbed residues upon
addition of fragment.
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Appendix F. STD-NMR of ZINC72447025 fragment with other SSB-Ct binding partners
represented in different colours: black-1D reference spectrum of ZINC72447025,
green-STD spectrum of E. coli χ, yellow-A. baumanni χ, dark green-RNAse HI and redPriA respectively.
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